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ABSTRACT 
Fluorometric Sedimentation Equilibrium for Lipoprotein Sub-class Analysis. 
 (December 2007) 
Ronald René Henriquez, B.S., University of Texas at Dallas 
Chair of Advisory Committee: Dr. Ronald D. Macfarlane 
 
Fluorometric density gradient ultracentrifugation is used to measure the 
lipoprotein density profile for cardiovascular disease risk assessment. The work 
presented establishes the effectiveness of using a single-spin separation as both an 
analytical tool and a preparative tool, while yielding valuable density information. This 
research expands on the analytical power of density gradient ultracentrifugation (DGU) 
by combining novel ethylenediaminetetraacetic acid (EDTA) gradient solutions, a 
fluorescent probe for analysis, and modern statistical methods for classification of heart 
disease risk.  
Sub-classes of lipoproteins are analyzed based on their density from the 
fluorescent lipoprotein density profile. The application of linear discriminant analysis 
(LDA) and sliced average variance estimation (SAVE) to the fluorometric DGU data 
yields a powerful classification tool. This method is capable of determining differences 
between control and cardiovascular disease patients that do not exhibit the traditional 
risk factors. The combination of these methods has great potential to serve as analytical 
tools for researchers in understanding the mechanisms of disease development and as a 
diagnostic tool for clinicians. 
 iv
DEDICATION 
 
 
 
 
To my parents Oscar and Rosa Henriquez 
and my brother Hector Henriquez. 
 v
ACKNOWLEDGEMENTS 
 
 I would like to acknowledge my advisor Dr. Ronald D. Macfarlane for his 
support and advice on my academic career and life goals. I would like to thank him for 
leading by example, for his guidance, and for teaching me the importance of our 
research.  
I would also like to thank my colleagues Leticia Espinosa, Richa Chandra, and 
Jeff Johnson for their collaborative efforts, advice and support over the years. Leticia 
Espinosa gave me valuable advice on the applications of our analytical methods on 
studying lipoproteins along with personal support over the years. I would like to 
acknowledge the support and collaborative efforts of Richa Chandra in the 
triglyceride/cholesterol relationship project development and to thank her for her support 
as well. I greatly appreciate the collaborative efforts of Jeff Johnson on the gradient 
separations and stoichiometry projects. His help and advice has been invaluable in these 
studies. 
I thank Dr. Catherine J. McNeal at Scott & White Hospital, Temple, Texas for 
the invaluable opportunity to assist in her ongoing clinical studies and for her 
collaborative efforts on this project, especially the development of a new classification 
method. I would also like to acknowledge Dr. Simon Sheather for his expertise and 
collaboration in the statistical classification project.  
I would also like to thank my committee members Dr. Manuel Soriaga, Dr. 
Vickie Williamson, and Dr. Stephen Smith for their support during my academic career. 
 vi
TABLE OF CONTENTS 
 Page
  
ABSTRACT……………………………………………………………………... iii
  
DEDICATION…………………………………………………………………... iv
  
ACKNOWLEDGEMENTS……………………………………………………... v
  
TABLE OF CONTENTS………………………………………………………... vi
  
LIST OF TABLES………………………………………………………………. viii
  
LIST OF FIGURES……………………………………………………………… ix
  
LIST OF ABBREVIATIONS…………………………………………………… xi
  
CHAPTER 
  
I        INTRODUCTION………………….……...………………………… 1
  
1.1  Significance………………………...……………………...... 1
1.2  Functional and Structural Description of Lipoproteins……... 2
1.2.1  Lipoprotein Classification and Properties……………. 3
1.2.2  Lipoprotein Subclasses………………………………. 5
1.3  Present Methods of Analysis………………………………... 7
1.3.1  Density Gradient Ultracentrifugation………………... 7
1.3.2  Other Methods of Analysis…………………………... 9
1.3.3  Quantitation of Cholesterol and Triglycerides……….. 14
1.4  Extrinsic Fluorophore Label………………………………… 16
1.5  Statistical Methods for Classification of Clinical Studies.….. 18
1.6  Application of Methods…………………..………………... 20
 
II       MATERIALS AND METHODS……………………….…………… 21
  
2.1  Materials……….……………………………………………. 21
2.1.1  Chemicals…………………………………………….. 21
2.1.2  Enzymatic Assays……………………………………. 21
2.1.3  CsBiEDTA Synthesis………………………………… 22
2.1.4  Cs2CdEDTA Synthesis………………………………. 22
2.2  Analytical Methods…………….…………………………… 23
2.2.1  Serum Collection.....…………………………………. 23
2.2.2  Fluorimetry…………………………………………... 23
2.2.3  Lipoprotein Density Profiling…………….………….. 24
2.2.4  Reproducibility of Density Gradient Measurement..… 27
2.2.5  Analysis of Serum Lipoprotein Fractions...………….. 31
 vii
CHAPTER Page
  
2.2.6  Approximation of LP/NBD Stoichiometry…………... 35
2.3  Clinical Studies………………..…………………………….. 36
2.3.1  Statistical Methods for Classifying CVD versus  
non-CVD Samples…………………………………… 
 
36
2.3.2  Measuring the Lipid Content of Lipoprotein 
Subclasses……………………………………………. 
 
37
2.3.3  Special Study: Effects of Statin Therapy on 
Lipoprotein Profiles………………………………… 
 
38
  
III      RESULTS AND DISCUSSION…………………………………….. 39
  
3.1  Analytical Methods………...……………………………….. 40
3.1.1  Saturation/Kinetic Studies…....……………………… 40
3.1.2  Lipoprotein Density Profiling………………………... 43
3.1.3  Reproducibility of Density Profile Measurement……. 51
3.1.4  Analysis of Serum Lipoprotein Fractions……………. 55
3.1.5  Approximation of LP/NBD Stoichiometry…………... 56
3.2  Clinical Studies………………………………........................ 61
3.2.1  Measuring the Lipid Content of Lipoprotein 
Subclasses……………………………………………. 
 
61
3.2.2  Statistical Methods for Classifying CVD versus non-
CVD samples ………………………………………... 
 
66
3.2.3  Special Study: Effects of Statin Therapy on 
Lipoprotein Profiles………………………………….. 
 
74
  
IV       CONCLUSIONS…………………………………………………… 78
  
REFERENCES…………………………………………………………………... 82
  
VITA……………………………………………………………………………... 89
  
 
 viii
LIST OF TABLES 
TABLE  Page
   
1 Differential lipoprotein characteristics…….…………...……….… 4
   
2 Lipoprotein subclasses analyzed using NaBiEDTA density 
gradient............................................................................................. 7
   
3 Lists the integrated fluorescence intensity values for the replicate 
measurements of the standard serum sample……………………….. 53
   
4 Competitive interactions of NBD C6-ceramide and lipoproteins… 58
   
5 Lists values for determining the stoichiometry of 9 randomly 
selected subjects…………………………………………………….. 60
   
6 Integrated fluorescence intensity values of 12 lipoprotein 
subclasses for 30 donors.…………………………………………… 68
 
 ix
LIST OF FIGURES 
 
FIGURE  Page
   
1 Basic composition of a lipoprotein…………………......……...…… 3
   
2 Enzymatic assay for cholesterol measurement …....……………… 15
   
3 Enzymatic assay for triglyceride measurement…...…...………..... 16
   
4 Structure of NBD C6-ceramide……………………………………... 17
   
5 Excitation and emission spectra of NBD C6-ceramide..……………. 18
   
6 Assembly of phantom tube………………………………..………... 30
   
7 Freeze slice method for excising lipoprotein fractions …….………. 32
   
8 Fluorescence response of major lipoprotein subclasses as a function 
of NBD C6-ceramide added shows that a minimum of 5µL of NBD 
C6-ceramide is required to saturate a 6µL sample of serum for a 
donor with moderately elevated lipid levels…...….…………...…… 41
   
9 Fluorescence evolution due to incorporation of NBD fluorophore 
into serum lipoproteins as a function of time………………………. 42
   
10 Fluorescence response of a lipoprotein sample before and after 
incubation with NBD C6-ceramide ….…………...………………… 43
   
11 Calibration curve relating refractive index of NaBiEDTA solution 
to density measured at 20°C……….…………...……….………….. 44
   
12 Gradient curve is constructed by taking aliquots sequentially from 
UC tube and comparing the refractive index to the calibration 
curve………………………………………………………………... 45
   
13 Image profile produced by the phantom tube………………………. 46
   
14 Density profile of 100 nm fluorescent polycarbonate spheres in 
0.2M NaBiEDTA gradient………………………………………….. 48
   
15 The density profile is generated by evaluating light intensity of the 
vertical central axis of the UC tube image.  The top of the tube is 
shown as the left position on the profile……………………………. 49
 
 x
 
FIGURE  Page
   
16 (a) Lipoprotein density profile (unlayered) in NaBiEDTA. (b) 
Lipoprotein density profile in NaBiEDTA following the layering of 
H2O…………………………………………………………………. 50
   
17 Shows the replicate profiles for a standard serum sample………….. 52
   
18 Density profiles for a single donor at various intervals.....……….… 54
   
19 Profile of a UC tube that has been scored to determine the precision 
of freeze/slice method.…….…………...……….…………………... 56
   
20 Shows the relationship between LDL integrated intensity versus 
cholesterol concentration for a single donor………………………... 62
   
21 a) Plot of bTRL fluorescence intensity versus TG concentration for 
a single donor b) Plot of dTRL fluorescence intensity versus. TG 
concentration for a single donor……………………………………. 63
   
22 Plot of LDL integrated intensity versus concentration of cholesterol 
for 10 donors………………………………………………………... 64
   
23 Show the relationship of Integrated fluorescence intensity for dTRL 
with respect to the TG concentration in the bTRL subclass………... 65
   
24 Show the relationship of integrated fluorescence intensity for bTRL 
with respect to the TG concentration in the bTRL subclass………... 66
   
25 Dot plot of LDL-3/HDL2b1.42 shows that use of this ratio correctly 
separates 25 (83%) of the samples and only 5 samples (17%) are 
overlapping with the opposite class………………………………… 70
   
26 A plot of the 2 dimensions of SAVE analysis reveals that there are 
two linear combinations that can distinguish between control and 
CVD subjects……………………………………………………….. 72
   
27 A 3-d plot of LDA and SAVE 73
   
28 a)Density profiles for placebo recipient b)Density profiles for statin 
recipient…………………………………………………………….. 76
 xi
LIST OF ABBREVIATIONS 
 
ACN Acetonitrile 
ALP Atherogenic Lipoprotein Phenotype 
Apo A-1 Apolipoprotein A-1 
Apo A-2 Apolipoprotein A-2 
Apo A-4 Apolipoprotein A-4 
Apo B-100 Apolipoprotein B-100 
Apo B-48 Apolipoprotein B-48 
Apo C-1 Apolipoprotein C-1 
Apo C-2 Apolipoprotein C-2 
Apo C-3 Apolipoprotein C-3 
Apo E-2 Apolipoprotein E-2 
Apo E-3 Apolipoprotein E-3 
Apo E-4 Apolipoprotein E-4 
bTRL Buoyant triglyceride-rich lipoprotein(s) 
CH3OH Methanol 
CM Chylomicron(s) 
CsBiEDTA Cesium bismuth ethylenediaminetetraacetic acid 
CVD Cardiovascular disease 
DGU Density gradient ultracentrifugation 
DMSO Dimethyl sulfoxide 
dTRL Dense triglyceride-rich lipoprotein(s) 
EDTA Ethylenediaminetetraacetic acid 
HDL High density lipoprotein(s) 
IDL Intermediate density lipoprotein(s) 
LDL Low density lipoprotein(s) 
LP Lipoprotein(s) 
Lp(a) Lipoprotein a 
MALDI-MS Matrix assisted laser desorption ionization mass spectrometry 
mm Millimeter 
NaBiEDTA Sodium bismuth ethylenediaminetetraacetic acid 
NBD 7-nitro-2,1,3-benz-oxadiazol-4-yl 
RLP Remnant lipoprotein(s) 
TAG Triglyceride(s) or Triacylglycerol(s) 
Tris-HCl Tris-hydrochloric acid 
TRL Triglyceride-rich lipoprotein(s) 
VLDL Very low density lipoprotein(s) 
A Absorbance 
ρ Density (g/mL) 
1 
CHAPTER I 
INTRODUCTION 
 
1.1 Significance 
Many large epidemiological studies have linked serum lipoproteins to 
cardiovascular disease (CVD).1-5 A series of independent risk factors, to assess a 
person’s risk for CVD, were set forth by these studies. In a recent report from the 
National Cholesterol Education Program (NCEP), the panel recommended that every 
person receive lipid screening consisting of total cholesterol, Low Density Lipoprotein 
cholesterol (LDL-c), High Density Lipoprotein cholesterol (HDL-c), and triglyceride 
measurements.6, 7 The values from the lipid screening are compared to NCEP guidelines 
and lipid-lowering therapy is initiated if deemed necessary. The guidelines set forth by 
the NCEP only take into consideration a small set of risk factors, but demonstrate the 
need for a rapid clinical method for risk assessment that yields the maximum amount of 
information. 
Lipoprotein particles can be separated and identified by density gradient 
ultracentrifugation (DGU). As a result, the literature contains many descriptions of 
density gradient methods for the isolation and preparation of lipoproteins. However, in 
the past DGU has been used primarily as a preparative technique not a quantitative 
analytical tool. So it was difficult to identify species of lipoproteins as CVD risk factors  
_________________ 
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from DGU alone. Other techniques used to analyze lipoproteins include gel 
electrophoresis,8 capillary isotachtophoresis,9 microchip capillary electrophoresis,10 gel 
permeation chromatography,11 NMR spectroscopy,12 and flotation centrifugation.13 
However, all still fundamentally rely on DGU as the standard method for separation 
because the definition of lipoprotein species is based on their hydrated densities.14 
Additionally, the use of EDTA metal complexes as gradient solutions for DGU have 
expanded the applicability of this technique.15, 16 The research described in this 
dissertation aims to expand the analytical power of DGU over current density gradient 
techniques used to generate lipoprotein profiles. This method is a result of three main 
improvements: the use of novel density gradients, staining with a fluorescent probe, and 
combining these methods with modern statistical methods. This novel method allows for 
the identification of a lipoprotein’s density and classification of risk for a sample. 
 
1.2 Functional and Structural Description of Lipoproteins 
 Lipoproteins are, in general terms, water-soluble macromolecules providing a 
mechanism for the transport of water-immiscible lipids in the blood stream and across 
cell boundaries. Lipoproteins can be classified according to their origin, function, 
composition or even method of isolation (i.e. density separation versus 
immunoseparation). Lipoproteins are micelle-like in structure since they contain a 
hydrophilic exterior and a hydrophobic core. A 2.05 nm thick surface shell of closely 
packed cholesterol and phospholipids surround this hydrophobic interior. The orientation 
of the phospholipid species polar heads and the free hydroxyl group of cholesterol is 
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such that they are aligned towards the external media to associate with the polar 
environment in the surrounding bloodstream. The fatty acid chains of the phospholipids 
and the sterol ring structure are in contact with each other and the hydrophobic core 
lipids. Figure 1 shows a typical lipoprotein structure.  
 
 
Figure 1. Basic composition of a lipoprotein. 
 
1.2.1 Lipoprotein classification and properties 
 Lipoprotein particles are classified mainly by their hydrated densities. It is 
important to keep in mind that this is an arbitrary classification system since the particles 
in reality exist more in a metabolic continuum, and are constantly interchanging 
identities and roles.17 The lipoprotein classes defined by hydrated density vary in their 
sizes, lipid content, and apolipoprotein content as well.14 The following table details the 
variation of lipoprotein characteristics (Table 1).18 The atherogenic lipoprotein 
phenotype consists of various characteristic conditions; elevated levels of total 
cholesterol, elevated levels of LDL cholesterol, high levels LDLIII, and elevated levels 
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of VLDL cholesterol.19 This research aims to expand ultracentrifugation method to 
detect as many of these characteristics via fluorescence imaging for simplification of the 
discovery phase of a patient’s diagnosis.   
 
Table 1. Differential lipoprotein characteristics. 
Lipoprotein 
Class 
Density (g/mL) Size 
(nm) 
Major Lipids Major apolipoproteins 
Chylomicron <0.93 100-500 Dietary TAGs B-48, C-II, E 
VLDL 0.93-1.006 30-80 Endogenous 
TAGs 
B-100, C-II, E 
IDL 1.006-1.019 25-50 CEs and TAGs B-100, E 
LDL 1.019-1.063 18-28 CEs B-100 
HDL 1.063-1.210 5-15 PL A, C-II, E 
Lp(a) 1.040-1.090 25-30 CEs  B-100 and glycoprotein 
 
Cholesterol and triglycerides are two lipid components found in lipoproteins 
involved in risk assessment for cardiovascular heart disease (CHD). Determinations of 
the distribution of these lipids are strong indicators used in diagnosing CHD, for 
example, LDL cholesterol and triglycerides. Lipoproteins are water-soluble 
macromolecules that transport lipids in the blood and to tissues. In 2001, certain classes 
of the lipoprotein population were identified as emerging risk factors for cardiovascular 
heart disease.20 Specifically, triglyceride-rich lipoproteins (TRL), chylomicrons and 
VLDL, are responsible for carrying the majority of the serum’s triglyceride content and 
LDL is responsible for carrying cholesterol and cholesteryl esters. The challenge is to 
develop methods that are clinically viable for the separation and quantitation of these 
species from human serum.  
 A convenient relationship between density and biological function exists in this 
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classification system for lipoproteins. As density decreases, the ratio of TAGs to 
phospholipids and cholesterol decreases. This is why chylomicrons (CM) and VLDL are 
classified as triglyceride-rich lipoproteins (TRL). The main function of this class of 
lipoproteins is the transport of triglycerides.21 
Lipoproteins in circulation are constantly being modified as they are 
metabolized; as such it is more beneficial to think of lipoproteins as a continuum. As a 
result each major class actually consists of a distribution of particles with slightly 
different sizes, compositions and densities. The major classes of lipoproteins can exhibit 
overlapping density ranges due to intermediate species. This evidenced by species that 
exist between LDL and HDL bands. Particularly two species that co-exist at about the 
same density are Lp(a), an LDL-like particle and apo-C1 enriched HDL.22-24 
Additionally, subtle differences in LDL and HDL composition contribute to broad 
density distributions.25, 26 However, these differences are typically minor, and result in 
only one band being visible for the subclass. 
 
1.2.2 Lipoproteins subclasses  
Chylomicrons primarily serve the function of transporting dietary fatty acids and 
are primarily synthesized in the post-prandial state in the small intestine.27 In an effort to 
minimize the interference of dietary lipids, typically blood is drawn after a 12 hour fast. 
Chylomicrons are a relatively short-lived lipoproteins that are rapidly hydrolyzed into 
chylomicron remnants.28  
 Very Low Density Lipoproteins (VLDL) serve as a vehicle for transporting 
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triglycerides and are synthesized in the liver. VLDL are continuously produced and 
metabolized into remnants. Hydrolysis of VLDL does not occur as quickly as 
chylomicrons, which gives VLDL a longer lifetime.  
 Experimentally, it is difficult to separate VLDL from chylomicrons in aqueous 
gradients due to overlapping densities that are less than 1 g/ml. As a consequence, 
recently two new classes were identified as buoyant triglyceride rich lipoproteins 
(bTRL) with a density <1g/mL and dense triglyceride rich lipoproteins (dTRL) with a 
density ~1g/mL. These were so named because they contain a mixture of apo B-48 and 
apo B-100 containing lipoproteins.29 
Intermediate Density Lipoproteins (IDL) are specifically a remnant of VLDL. 
IDL is formed as a result from further hydrolysis of VLDL remnants. IDL exists in a 
region of density from 1.0006-1.019. IDL is typically short lived and is quickly cleared 
by endocytosis or is converted into LDL.14 
Low Density Lipoproteins (LDL) are predominantly composed of cholesterol 
esters and Apo B-100. The primary function is transporting cholesterol to peripheral 
tissue. Five subclasses of LDL have been identified by equilibrium density gradient 
ultracentrifugation; LDL-1 (1.019 – 1.023 g/mL), LDL-2 (1.023 – 1.029 g/mL), LDL-3 
(1.029 – 1.039 g/mL), LDL-4 (1.039 – 1.050 g/mL) and LDL-5 (1.050 – 1.063 g/mL).30  
High Density Lipoproteins (HDL) primarily serve to remove cholesterol from 
tissue in reverse cholesterol transport. This process involves the transfer of lipids and 
apoliproteins to and from the other lipoproteins. HDL regulates the other lipoprotein 
fractions by this process. Two overall subclasses of HDL have been identified, HDL2 
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and HDL3.31 HDL was further subdivided into fractions HDL2b (1.063-1.091 g/mL), 
HDL2a (1.091-1.110 g/mL), HDL 3a (1.110 –1.133 g/mL), HDL 3b (1.133 –1.156 g/mL) 
and HDL 3c (1.156 –1.179 g/mL) by sequential centrifugation followed by density 
gradient ultracentrifugation.30, 32  
Table 2 lists the major lipoprotein subclasses and their density ranges. This also 
includes the newly defined subclasses of buoyant and dense TRL. 
 
Table 2. Lipoprotein subclasses analyzed using NaBiEDTA density gradient.  
 
 
1.3 Present Methods of Analysis 
1.3.1 Density gradient ultracentrifugation 
 Density gradient ultracentrifugation is the primary standard method for the 
separation and identification of lipoproteins by density. Since lipoproteins are classified 
mainly by their hydrated densities, it is advantageous to utilized DGU for the analysis of 
serum lipoprotein. Lipoproteins were originally separated sequentially by removing the 
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lower density lipoproteins from the denser lipoproteins through sequential flotation.14, 
30As the lipoprotein density increases the flotation rates dramatically decrease. For 
example, HDL (high density lipoprotein) has a hydrated density range of 1.063-1.21 
kg/L and have a flotation rate between 0 and 9 Sf, which is much lower than 
chylomicrons, the least dense class of lipoproteins (>0.94 kg/L), that have a flotation rate 
greater than 400 Sf. 30 
Rate zonal ultracentrifugation and isopycnic ultracentrifugation are the primary 
methods used for separating serum lipoproteins. These methods commonly employ 
solutions of sucrose or salts such as NaCl or KBr for separation. 30, 33, 34 The flotation 
and sedimentation rates are proportional to the viscosity of the solution, molecular 
weight of the particle, applied centrifugal force, and the difference between the density 
of the particle and the density of the solution utilized.30 
Lipoproteins are typically separated by sequential flotation due to a highly 
controlled density separation. Rate zonal ultracentrifugation separates lipoproteins by 
sequentially floating lipoprotein particles by adjusting of the solution density. Basically, 
a separation is achieved by layering a less dense solution over serum, and during 
ultracentrifugation the more buoyant lipoproteins float to the top. The top fraction is then 
collected, typically by aspiration.35 This is then repeated, as necessary, to collect all 
desired fractions.30 This method can be very time consuming but is very effective given 
sufficient sequential steps.  
In isopycnic ultracentrifugation, a density gradient is created where the density 
increases from the top to the bottom, and the lipoproteins settle into zones where the 
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density of the solution is equal to the density of the lipoproteins. This method is often 
preferable to rate zonal ultracentrifugation in that it achieves more quantitative 
separation.36 Other density separation methods have been created that employ 
characteristics of both techniques and cannot be classified.30 Density gradients used in 
centrifugal separation are available as either self-generating or pre-generated. Self-
generating gradients are easy to produce and information regarding the resulting gradient 
is also easy to assess.34 Recently, separations requiring only a single spin were reported 
involving sucrose, CsBiEDTA, and other metal ion complexes of EDTA. These 
procedures involve shorter centrifugation times and easier sample preparations. 15, 16, 37 
To visualize locations of the lipoproteins some lipophilic dyes are employed such 
as Fat Red and Sudan Black B which are colorimetric dyes.38, 39 Recently, a fluorescent 
probe, NBD C6-ceramide, has been used in capillary isotachophoresis and density 
gradient ultracentrifugation to visualize lipoproteins.9, 15, 16, 23, 29, 40 Lipoproteins labeled 
with this fluorophore can be detected utilizing very low concentrations of the dye. 
Additionally, a strong relationship between NBD C6-ceramide and similar analogs with 
LDL and HDL cholesterol concentrations has previously been observed.9, 41, 42 
 
1.3.2 Other methods of analysis 
 At present there are multiple techniques available for the compositional study of 
lipoproteins, four of which have been made commercially available to clinicians through 
resource laboratories; gradient gel electrophoresis (GGE), ultracentrifugation-vertical 
auto profile (VAP), nuclear magnetic resonance (NMR), and tube gel electrophoresis 
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(TGE). However, it is rather alarming and disconcerting that the degree of agreement 
between these techniques is low.11, 12, 43-49 This disparity renders the use of these 
techniques unreliable and limits the usefulness in the clinical setting.  
 
1.3.2.1 Gradient gel electrophoresis 
 To assess the severity of the atherogenic lipoprotein phenotype, Berkeley Heart 
Lab uses LDL Segmented GGE.50 This technique is primarily based on the work of 
Krauss and coworkers.51, 52 GGE operates by separating the LDL subclass into 7 
subfractions based on shape and size. The subfractions are reported as percentages based 
on areas under the curve. Small LDL particles correspond to the LDL IIIa/b and are an 
indication of the atherogenic lipoprotein phenotype. While this technique’s strength lay 
in the analysis of LDL’s subfractions, it is incapable of providing any information about 
the other major lipoprotein subclasses that may contribute to atherosclerosis. It is not 
possible to determine the relationship of LDL to HDL, which is a strong reference tool 
currently used for determining a patient’s prognosis. 
 
1.3.2.2 Ultracentrifugation-vertical auto profile 
 Kulkarni and coworkers developed the ultracentrifugation-VAP technique used 
by Atherotech.53 The VAP-II generates a series of absorbance curves to produce 6 LDL 
subclasses. This technique uses a single spin vertical UC separation tuned specifically to 
separate LDL subclasses and then uses an online cholesterol absorbance analyzer to 
generate the LDL curves and cholesterol concentrations. Though this technique is 
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capable of determining information about the LDL subclasses relatively quickly there is 
no information about other lipoprotein subclasses without performing a more 
experimentation. 
 
1.3.2.3 Nuclear magnetic resonance 
 Liposcience, Inc. provides lipoprotein analysis by use of proton NMR.54 Each 
subclass produce highly specific proton NMR patterns when analyzed for distinctive line 
shapes. Each subclass of lipoproteins has slightly different spectra by comparison of the 
methyl resonance from the lipids contained in isolated VLDL, LDL, and HDL. These 
lines could then be fit to a composite NMR spectrum where the lipoproteins are not 
previously separated. The benefit of this technique is that does not require a preparatory 
separation. This technique has reportedly high agreement with GGE. However at this 
time it is unclear as to the accuracy of cholesterol measurements provided by this 
technique due to the highly complex nature of analysis required to analyze resulting 
spectra. 
 
1.3.2.4 Tube gel electrophoresis 
 The tube gel electrophoresis kit produced by Kronos Science Laboratories, Inc. is 
designed specifically for the analysis of LDL subfractions. It compares the 
electrophoretic mobility of LDL subfractions to that of standard particles to estimate 
LDL size.8 Measurement of cholesterol must be conducted separately and is typically 
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performed by enzymatic assay. At this time there is still much debate as to the role and 
importance of size of a lipoprotein plays, if any.55, 56 
 
1.3.2.5 Friedewald method 
 Due largely to inconsistencies and costs of many of the new technologies has led 
many clinicians to be reticent to adopt the new approaches. To date the most widely used 
method for cholesterol measurement is Friedewald’s method reported in 1972.57 The 
Friedewald method involves measuring the total cholesterol and total triglycerides by 
enzymatic methods. Then rapid precipitation is used to separate HDL and measure the 
HDL cholesterol. After these measurements are performed use of the Friedewald 
equation estimates the LDL cholesterol levels (Equation 1). 
 
CLDL =  CPlasma -  CHDL - TG/5     (Equation 1) 
 
The Friedewald equation has been a useful clinical tool for many years. 
However, it is desirable to have a direct measurement of LDL cholesterol and not simply 
an indirect estimation. 
 
1.3.2.6 Lipoprotein component analysis 
 While much of the lipoprotein characterization research has over the past half 
century focused on properties of the intact lipoprotein particles, recent advances in 
characterization technology has brought into focus the constituents of the lipoproteins, 
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specifically, the protein component (apolipoprotein). For example, capillary 
electrophoresis can be tailored to characterize and quantify the apolipoproteins by 
capillary electrophoresis.58-60 Characterization of the apolipoproteins by mass 
spectrometry have also proven to be a significant addition to the field. Several studies on 
the use of matrix-assisted laser desorption mass spectrometry (MALDI-MS)61, 62 to study 
isoforms and post-translational modifications of the apolipoproteins have stimulated 
studies on apolipoprotein characterization by mass spectrometry and using proteomics 
technology. 63 64, 65 
During the past decade, several studies have been carried out characterizing 
serum apolipoproteins by MALDI-MS.66-68 Numerous post-translational modifications 
of the apolipoproteins have been identified, indicating that during their lifetime in 
circulation, the lipoproteins are exposed to domains in the circulatory system that modify 
their structures.62, 69 Little is known about the origin or function of these modifications.  
While HDL plays a major role in maintaining a healthy lipid metabolism, recent 
evidence suggests that there are forms of HDL that are involved in the development of 
cardiovascular disease.70 Recent findings show that a form of HDL containing apoC-I is 
associated with newborns that are smaller than gestational age (SGA).22 These SGA 
infants tend to develop cardiovascular disease at an early age. A clinical study involving 
adults with cardiovascular disease who have high HDL cholesterol levels and normal 
LDL levels was prompted by this observation. Five HDL subclasses have been identified 
from previous studies covering a density range from 1.063 – 1.179 g/mL. A 
comprehensive analytical protocol has been developed for the analysis of these 
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lipoprotein subclasses based on their density.15, 16, 29 Isopycnic fast ultracentrifugation 
coupled with a novel metal-ion EDTA density-forming solute is used to resolve the 
lipoprotein subclasses.16 A high resolution lipoprotein particle density profile is 
generated using fluorescence image analysis.9, 15  
 
1.3.3 Quantitation of cholesterol and triglycerides   
 Many analytical techniques for the measurement of cholesterol and triglyceride 
content of lipoproteins exist. Currently, the CDC (Center for Disease Control) approved 
measurement of total cholesterol is based on the work of Sperry and Brand. This is a 
colorimetric assay based on the hydrolysis of cholesterol esters and the reaction of 
purified cholesterol with a color-producing reagent.71 
 Routine laboratory measurement of cholesterol is based on enzymatic methods and 
has largely replaced the chemical approach of Sperry and Brand. These methods are 
more specific and can be automated. Generally these methods involve the hydrolysis of 
cholesterol esters by cholesterol esterase, an enzyme, to release cholesterol and fatty 
acids. The cholesterol is then oxidized by cholesterol oxidase to produce hydrogen 
peroxide (H2O2) as a side product. Measurement of H2O2 is the most common method to 
quantify cholesterol.  The H2O2 molecule reacts with two substrates by peroxidase to 
produce a quinonimine dye that can then be measured at 540 nm.72 Figure 2 details the 
reactions necessary for the measurement of cholesterol in this manner. 
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Figure 2. Enzymatic assay for cholesterol measurement. 
 
 Likewise, most clinical laboratories utilize enzymatic methods to analyze 
triglyceride concentration. This measurement involves hydrolysis of triglycerides into 
glycerol and fatty acids by lipase. Glycerol is then phosphorylated by a kinase to 
produce glycerol-1-phosphate. This molecule is then oxidized to produce H2O2, and as in 
the case of the enzymatic cholesterol assay, H2O2 is reacted with two chromogenic 
substances to produce quinoneimine dye that can then be visually detected by 
spectrometry.73 The figure 3 details the reactions necessary for the measurement of 
triglycerides in this manner.  
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Figure 3. Enzymatic assay for triglyceride measurement. 
 
1.4 Extrinsic Fluorophore Label 
Lipophilic molecules, such as NBD C6-ceramide, have been used to fluorescently 
label lipoproteins.9, 15 NBD C6-ceramide, shown in figure 4, is unique in that it only 
fluoresces when it is incorporated into a hydrophobic environment. This makes it highly 
specific to lipoproteins in a serum sample.74 Additionally, fluorescence techniques have 
inherently high sensitivity and low background interference. NBD C6-ceramide has also 
shown to be a good analog to serum lipids and its fluorescence correlates to the primary 
non-polar component of a lipoprotein.9 With the combination of fluorescence labeling 
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and DGU, classification of patient risk level can be determined from the lipoprotein 
profile. 
 
 
Figure 4. Structure of NBD C6-ceramide. 
  
 To understand the relationship of lipoproteins to NBD C6-ceramide, it is 
important to operate under equilibrium conditions to ensure that all lipoprotein 
subclasses have sufficiently incorporated the fluorophore. Figure 5 show the 
characteristic excitation and emission spectra for NBD C6-ceramide. The primary 
difficulty of using NBD C6-ceramide, as a quantitative tool, has been that two 
populations of NBD exist: NBD in fluorescently favorable and unfavorable domains of 
lipoproteins.  
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Figure 5. Excitation and emission spectra of NBD C6-ceramide.  
 
1.5 Statistical Methods for Classification of Clinical Studies 
In response to the need for rapid classification and identification of a patients 
health, many studies are beginning to employ modern statistical methods in clinical 
studies.75  Data derived from the lipoprotein density profile are used to classify CVD 
subjects and healthy controls using these modern statistical methods for classification 
analysis. The classification analysis also ranks those lipoprotein subclasses according to 
their influence on classification. 
 In one such study, lipoprotein particle size was used as the defining parameter as 
measured by HPLC.75  This clinical study included three parameters for the subclass 
analysis.  For the two group classification, with and without CVD, a linear 
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discrimination approach was applied using the receiver operating curve (ROC) method 
to accommodate three lipoprotein subclass variables. The efficiency of the group 
classification is expressed in terms of “area under the curve” (AUC) with a value of one, 
representing 100 % accuracy in classification.76  A linear combination of three variables 
derived from the subclass analysis gave the best classification accuracy (AUC = 0.773), 
compared to the best performing of the traditional variables (LDL-c/HDL-c) with an 
AUC = 0.748.  
 Other stastical methods developed for such studies include, Fisher’s linear 
discrimination analysis (LDA) as one of the classification models.77, 78 LDA seeks to 
find a linear combination of the predictor variables which best separates the two groups 
in terms of the mean of this linear combination. This is a very powerful tool for handling 
a larger data matrix of variables. In addition, newer methods including recursive 
partitioning (RP),79, 80 sliced average variance estimation (SAVE), and sliced mean 
variance covariance (SMVCIR).81 have proven to be very useful tools in clinical 
studies.82 The SAVE and SMVCIR approaches to classification are based on searching 
for linear combinations of the predictor variables which best separate the groups in terms 
of mean, variance and covariance of these linear combinations. Several recent methods 
have shown that classification can be improved in practice, often dramatically, if 
variance and covariance differences are considered as well as mean differences. 81, 82 
When these methods as combined such as, combining LDA and SAVE or LDA and 
SMVCIR, as a 3-dimensional analysis the result leads to improved classification.  
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1.6 Application of Methods 
 The goal of these methods is to make clinical applicable techniques that 
will aid in understanding the factors affecting a patient’s risk for cardiovascular heart 
disease as well as classification. The methods of profiling the distribution of lipoproteins 
provide a snapshot that indicates the levels of all lipoprotein subclasses in one 
experiment. The fluorescence tag NBD ceramide mimics the chemical behavior of lipids, 
and can potentially yield a quick method for the quantitation of triglyceride and 
cholesterol. By combining DGU with the enzymatic assays and MALDI provides a 
strong analytical tool for determining fundamental compositions of lipoproteins. In the 
study reported here, our objective was to determine whether the pattern of post-
translational modifications previously observed for apo A-I are the same throughout the 
HDL density profile.  This information is part of an ongoing program to better 
understand features of the population of circulating lipoproteins at the molecular level. 
 Finally combining DGU with modern statistical methods can provide a powerful 
classification tool. The strength of these methods is the ability to analyze many aspects 
of an individual’s lipoprotein profile to attain an overview of a patients risk. It is 
reported that approximately 80% of patients that develop CVD have the traditional risk 
factors.83 The other 20% results in an alarmingly high number of people that never 
realize they are at risk for CVD until it is much too late. The work reported here 
establishes a method to distinguish between CVD and non-CVD donors that do not have 
the traditional risk factors.  
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CHAPTER II 
MATERIALS AND METHODS  
 
2.1 Materials 
2.1.1 Chemicals  
 NBD C6-ceramide and Fluospheres (0.1 µm carboxylate modified red fluorescent 
microspheres) were purchased from Molecular Probes (Eugene, OR). NaBiEDTA 
(C10H12N2O8NaBiy4H2O) was purchased from TCI America (Portland, Oregon). 
Poly(dimethyl siloxane) (PDMS) elastomer  Sylgard 184 was purchased from Dow 
Corning (Midland, MI). Toluene, TFA, EDTA, ferulic acid, cesium carbonate, cadmium 
carbonate, and dichloro-tris (1,10-phenanthroline) ruthenium(II) hydrate purchased from 
Sigma-Aldrich (St. Louis, MO). Bismuth carbonate oxide was purchased from Alfa 
Aeser Co. (Ward Hill, MA). Acetonitrile, DMSO, and methanol were purchased from 
EM Science (Darmstadt, Germany). 
 
2.1.2 Enzymatic assays 
Cholesterol analysis was performed with InfinityTM cholesterol reagent, Lipid 
Control Levels 1 and 2, and cholesterol standard purchased from Thermo Electron 
Corporation (Waltham, MA). The triglyceride measurements were performed from the 
following reagents purchased from Sigma-Aldrich (St. Louis, MO): triglyceride reagent 
(catalog number T2449), free glycerol reagent (catalog number F6428), and glycerol 
standard (catalog number G7793). Commercial immunoassays for the determination of 
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concentration of apolipoprotein A-I and B were purchased from Wako Diagnostics 
(Richmond, VA).  
 
2.1.3 CsBiEDTA synthesis 
 The CsBiEDTA complex was synthesized from H4EDTA, the appropriate alkali 
carbonate; and the bismuth oxycarbonate.84, 85 The reagents were combined 
stoichiometrically in 100 mL of DI H2O, followed by a 2-h reflux, yielding a clear 
solution. Cesium carbonate was then added to the clear solution to bring the final pH 
range to 6-7. The final solution volume was reconstituted to 100 mL to account for 
evaporation during reflux to give stoichiometric solutions with a final concentration of 
0.200 M.  
 
2.1.4 Cs2CdEDTA synthesis 
The Cs2CdEDTA complex was synthesized from H4EDTA, cesium carbonate, 
and cadmium carbonate.84, 85 The reagents were combined stoichiometrically in 100 mL 
of DI H2O, followed by a two hour reflux, yielding a clear solution.  The cesium 
carbonate was added to the clear solution to bring the final pH range to 6-7.  The final 
solution volume was reconstituted to 100 mL to account for evaporation during reflux to 
give stoichiometric solutions with a final concentration of 0.300 M. 
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2.2 Analytical Methods 
 
2.2.1 Serum collection 
Serum samples were collected by a blood draw into a 9 mL Vacutainer tube 
(Beckton Dickinson Systems, Franklin Lakes, NJ) treated with a polymer gel and silica 
activator, and the serum was separated from red blood cells by centrifugation at 3200 
rpm for 20 min at 4°C. The supernatant (serum) was aspirated from red blood cells and 
stored at -80°C prior to analysis. Informed consent was obtained from donors.  
 
2.2.2 Fluorimetry 
2.2.2.1 Determination of serum LP saturation with fluorescent label  
The amount of NBD C6-ceramide required to saturate a 6 µL serum sample was 
determined by monitoring the fluorescence response of the lipoprotein subclasses as a 
function of fluorophore content. NBD C6-ceramide was received as 1mg solid from the 
manufacturer, and the solution is prepared by adding 1ml of DMSO to the solid. The 
resulting solution is 1mg/mL of NBD C6-ceramide in DMSO. Serum samples were 
prepared by mixing 6µL of serum, with 84 µL of H2O and 1100 µL CsBiEDTA. Then 
varying volumes of NBD and H2O were added the samples while maintaining a constant 
total volume across all samples: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10µL of 1 mg/mL NBD 
C6-ceramide and 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, and 0 µL of H2O respectively.  
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2.2.2.2 Determination of serum LP uptake of fluorescent label as a function of time 
Required incubation time of NBD C6-ceramide with serum lipoproteins was 
determined by monitoring the evolution of fluorescence over time using an SLM-
Aminco spectrofluorometer. Serum sample was prepared by mixing 6µL of serum, with 
84 µL of H2O and 1100 µL CsBiEDTA. A 1mL aliquot of serum solution is added to a 
quartz cuvette and stirred continuously. Then 10 µL 1 mg/mL NBD C6-ceramide is 
added to the cuvette and a fluorescence time trace is generated by monitoring the 
increase in fluorescence with an excitation at 450 nm and emission at 520nm. 
Fluorimeter slits widths were set to 4, integration time of 1 second, and a resolution of 1 
second for the time trace and 1 nm for the emission scan.  
 
2.2.3 Lipoprotein density profiling 
2.2.3.1 Hydrodynamic properties of NaBiEDTA solutions  
A series of ten NaBiEDTA solutions were made for the construction of 
calibration curves necessary for relating density and refractive index to concentration. 
The density of each solution was determined gravimetrically with a calibrated 10-mL 
glass pipet. Partial specific volumes were calculated from the solution densities. The 
refractive index of each solution was measured at 20 °C using an Abbe 60/DR 
refractometer from Bellingham + Stanley (Lawrenceville, GA). 
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2.2.3.2 Gradient formation and measurement 
Density gradients were formed in an Optima TLX ultracentrifuge, TLA 120.2 
fixed-angle rotor, and 1.5-mL, thick-walled, polycarbonate, ultracentrifuge tubes 
(Beckman-Coulter, Palo Alto, CA). All tubes contained 1000µL and were centrifuged at 
5 °C. A Rotor speed of 120,000 rpm for 6 hours was used. For the TLA120.2 rotor, these 
speeds correspond to average relative centrifugal force of 511000g. After centrifugation, 
gradient shapes were determined by removing 20µL aliquots from discrete positions 
within the gradient and measuring their refractive index. Each tube was sampled 
sequentially from the top so that the gradient below each aliquot was not disturbed. 
Tubes were imaged while the sample was being removed so the exact location of each 
aliquot could be determined by digital analysis. 
 
2.2.3.3 Ultracentrifugation of serum samples  
Ultracentrifugation of the serum was performed to obtain density profiles as 
follows. For serum density profiling, 6 µL of serum and 84 µL of H2O were added to 
1100 µL of the NaBiEDTA followed by the addition of 10 µL of the 1 mg/mL NBD C6-
ceramide in DMSO. A 1000 µL aliquot of this solution was ultracentrifuged in a 1.4 mL, 
34 mm long, polycarbonate thickwall ultracentrifugation tube (Product Number 343778, 
Beckman-Coulter, Palo Alto, CA) at 120,000 rpm for 6 hours at 5ºC in an Optima TLX 
ultracentrifuge, TLA 120.2 fixed-angle rotor (Beckman-Coulter, Palo Alto, CA). 
Following the spin, 200 µL of H2O was layered on top of the tube contents for each 
sample for the separation of buoyant and dense TRL.  
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2.2.3.4 Image analysis 
Following the spin and layering, an image of the tube was obtained and analyzed 
using a digital Optronics Microfire Camera (S99808, Goleta, CA) with a Fiber-Lite MH-
100 Illuminator, (MH100A, Edmund Industrial Optics). The light source described here 
is a metal halide continuous light source. The camera is a digital color microscope 
camera (S99808, Optronics, Goleta, CA). The camera and light source were placed 
orthogonally to each other on an optical bench to illuminate the sample suspended in a 
post holder. Two filters matching the excitation and emission characteristics of NBD C6 
ceramide from Schott Glass (Elmsford, NY) were chosen. A blue-violet filter (BG-12) 
with a bandwidth centered at 407 nm and a yellow emission filter (OG-515) with a 
bandwidth centered at 570 nm were used as the excitation and emission filters 
respectively. Specific settings for the Microfire camera software were an exposure of 
15.8 mS with a gain of 1.000 and a target intensity of 30% to illuminate the tube prior to 
image capture this prevent image saturation. 
The image of the tube following ultracentrifugation was then converted to a 
density profile using the described method.16 The image was converted from pixel values 
into intensities versus tube coordinates (0-34 mm) of the polycarbonate 
ultracentrifugation tube by Origin 7.0 software to create a lipoprotein density profile. 
This entire protocol was applied to the serum analysis.  
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2.2.3.5 Biological variability 
 Biological effects that may affect serum profile were measured by profiling the 
serum of a donor as described above at the following interval: 1 day, 1 month, and 1 
year.  
 
2.2.4 Reproducibility of density gradient measurement 
 
2.2.4.1 Replicate measurement of nanosphere standard in NaBiEDTA density gradient 
 Replicate measurements of the gradient were performed to evaluate the 
reproducibility of the gradient formation by measuring the position of polycarbonate 
fluorescent beads in the gradient. Samples were prepared by mixing 1100µL of 
NaBiEDTA with 50µL of H2O and 50 µL of sphere solution containing 3.60 × 109 
particles/mL. Ultracentrifugation was performed as described above. Imaging was 
performed as described above with minor modification using a green excitation filter 
(VG-6) with a bandwidth centered at 520 nm and a red emission filter (R-60) with a low 
cutoff at 600 nm. Twenty replicate measurements were performed.  
 
2.2.4.2 Replicate measurement of standard serum sample in NaBiEDTA density gradient 
 The reproducibility of NBD’s fluorescence response and density gradient was 
assessed by replicate measurements of a standard serum sample. Ten replicate 
measurements of the density profile were completed as described in section 2.2.3.3 on a 
standard serum sample. 
  28 
 
2.2.4.3 Phantom tube 
 A phantom tube is used to assess certain response features of the imaging system. 
The phantom tube is constructed to mimic a lipoprotein density separated tube with 
similar fluorescence features containing both fluorescent and non-fluorescent layers. 
Fluorescent layers were made using a dichloro-tris (1,10-phenanthroline) ruthenium(II) 
hydrate solution containing 10 mg/ml of the ruthenium in a 4:1 (v:v) mixture of 
methanol and toluene, respectively. 
Two solutions of PDMS elastomer are prepared to make the fluorescent and non-
fluorescent layers. For a non-fluorescent layer, 4.5 g of PDMS is poured into a 
disposable measuring dish and 0.5 g of curing agent is then added. The solution is mixed 
for 3 minutes with a disposable spatula, and then a vacuum is applied over the mixture to 
remove bubbles from the solution.  
For the fluorescent layer, 4.5 g of PDMS is poured into a disposable measuring dish 
and 0.5 g of curing agent is then added. Then 50 μL of pre-made ruthenium solution is 
added to the mixture. Solution is mixed for 3 minutes with a disposable spatula (the 
color turns slight orange), and then a vacuum is applied over mixture to remove bubbles 
from the solution.  
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The assembly of the phantom tube, as shown in figure 6, is made by first forming 
appropriate discs of alternating fluorescent and non-fluorescent layers. (a) An empty UC 
tube is cut with appropriate height and ends are polished at each side. (b) The tube disk 
is placed on a microscope slide (or plastic Petri dish). (c) PDMS solution is poured 
slowly into the tube to avoid formation of bubbles in the solution. (d) The top is 
carefully covered with a slide to avoid bubbles. PDMS is cured for 1 hour at 80°C in 
oven. (e) PDMS disk is removed from the tube mold, and the ends of the disc are cut to 
remove residues on the PDMS with scissors or knife. (f) Each disk is cleaned with H2O 
and then the disks are placed together alternating fluorescent and non-fluorescent layers. 
(g) An empty UC tube is prepared by drilling a small ventilation hole on the bottom of 
the tube (~ 1 mm diameter) The disk assembly is then pushed into the UC tube. (h) The 
bottom concave cavity is then filled with clear PDMS using a syringe and polymerized. 
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Figure 6. Assembly of phantom tube. 
  31 
2.2.5 Analysis of serum lipoprotein fractions 
 
2.2.5.1 Lipoprotein fraction collections 
The major lipoprotein classes were collected using a novel freeze/slice method. 
Tubes were placed in a custom built holder and secured to a ring stand. A Dewar flask 
filled with liquid nitrogen was raised with a jack stand until the liquid nitrogen just 
touched the bottom of the tubes. The gradient froze slowly from the bottom up. This 
method does not distort the gradient but there is a shift due to the expansion of water 
going from the liquid to the solid state. The cut points determined from the profile are 
corrected for this effect using the following equation. 
 
mm f = ρlρs × mml −10.405 =1.058 × mml −10.405  (Equation 2) 
 
The mml represents the tube coordinate in millimeters from the lipoprotein 
density profile. Since the density gradient solution expands upon freezing, this equation 
corrects for the expansion yielding a frozen state cut point, mmf. The expansion is 
accounted for by a ratio of the density of water in liquid state, at lab temperature, to the 
density of water in the solid state. In addition, 10.405 mm was subtracted from the 
frozen state cut point to adjust for the calibration of the micrometer/tube holder 
assembly.  
The frozen tubes were placed in a custom-built stainless steel cutting block. A 
micrometer head in the block is used to advance the tube relative to a notch for the 
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blade. A Dremel® scroll saw (model 1672, Racine, WI) fitted with 0.25mm wide blades 
(cat. #16413) was used to cut the tubes. Figure 7 depicts the freeze/slice method for 
excising lipoprotein fractions.  
After collecting the lipoprotein fractions into fresh tubes further analysis can be 
performed to characterize the fractions individually. This includes but is not limited to 
MALDI-MS, enzymatic assays, and CE.  
 
 
Figure 7. Freeze slice method for excising lipoprotein fractions. 
 
 After determining the cut points required for collecting lipoprotein fractions 
(mmf), a UC tube was scored at those defined locations using the Dremel scroll saw and 
the tube holder. The scored tube was imaged to determine the precision of the slicing 
method by comparing actual cut positions to the ideal cut positions determined by 
equation 2. 
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2.2.5.2 Determination of Apo A-I and B concentration 
The commercial immunoassays were adapted to determine the concentrations of 
apo A-I and B in the lipoprotein fractions collected from the ultracentrifuge separation. 
A manual procedure provided by Wako, was followed with the exception of an increase 
in the sample volume to 30µL. An aliquot of 30µL of the fraction was added to the well 
followed by 175µL reagent 1 (Buffer). The plate was incubated at 37°C for 5 minutes, 
and then absorbance was read at 700nm. This measurement served as a sample blank. A 
25 µL aliquot of Reagent 2 (antibody) was added to the sample.  Again the plate was 
incubated at 37°C for 5 min then absorbance was measured at 700 nm. Apolipoprotein 
concentrations were calculated based on a calibrator containing 130mg/dL apo A-I and 
80mg/dL apo B. Volumes of the lipoprotein fractions were determined gravimetrically in 
order to determine the molar concentration of apolipoproteins in the LDL and HDL. 
 
2.2.5.3 Cholesterol assay 
 Cholesterol analysis was performed according to the manufacturers’ instructions 
as follows. Two 30μL aliquot of each LDL fraction and two 3μL aliquot of a 200mg/dL 
cholesterol calibrator were added to a 96-well microtiter plate. A volume of 300μL of 
enzymatic cholesterol reagent was added to each well containing sample or calibrator 
and incubated for 5 minutes at 37oC for five minutes. The absorbance of the plate was 
measured at 500nm with water used at the blank. The average absorbance value of the 
blank was subtracted from all the absorbance values to obtain corrected absorbance 
values. The cholesterol concentrations for the LDL samples were then calculated from 
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the linear regression equation of prepared cholesterol standards.  
 
2.2.5.4 Triglyceride assay 
Triglyceride measurements were performed according to manufacturers’ 
instructions (Sigma Aldrich). These reactions are detailed in Figure 3. The glycerol 
standard, blank (H2O), and 3 µL aliquots of the lipoprotein fractions were assayed with a 
300 µL volume of prepared triglyceride working in a 96-well microtiter plate. The plate 
was incubated for 5 minutes at 37 ºC after which absorbance values at 540 nm were 
measured for all standards, blank, fractions, and serum. The absorbance of the blank was 
subtracted to obtain corrected absorbance values for the standard and samples. The 
triglyceride concentration was determined by the following equation. 
 
 mg/mL) (2.5 Standard of Conc. 
A-A
AA
blankstandard
blanksample ×−   (Equation 3) 
 
 The absorbance values at 540 nm for the sample (Asample) and standard (Astandard) 
were corrected by subtracting the absorbance value of the blank (Ablank). The triglyceride 
concentrations were then calculated against the absorbance (Astandard) and theoretical 
concentration of the glycerol standard (2.5 mg/mL or 250 mg/dL).  
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2.2.6 Approximation of LP/NBD stoichiometry  
 In this method the ratio of NBD to a lipoprotein was measured in different 
lipoprotein fractions separated by density gradient ultracentrifugation and comparison to 
a standard sample of NBD C6-ceramide. These values were used to determine percent 
distribution throughout the lipoprotein classes as a function of density. The number of 
fluorophores that were incorporated into a favorable dielectric environment in a serum 
sample is determined by comparison with an NBD sample in chloroform from the 
integrated fluorescence intensity. Additionally the effect of ultracentrifugation on the 
fluorescence intensity of a serum sample was measured.  
The chloroform standard was prepared in a glass vial by adding 6 µL of NBD 
followed by 1112 µL of chloroform. Then 1mL of the solution was dispensed into a UC 
tube for imaging. Imaging was performed using the following imaging conditions: 
Exposure time: 3.67 ms and Gain: 1.000. 
Serum samples were prepared in an Eppendorf tube by adding 6 µL of serum, 10 
µL of 1 mg/mL NBD, 84 µL DI H2O, and 1100 µL of 0.2 M CsBiEDTA (pH=6.92). The 
serum sample was imaged prior to and after UC separation. Imaging was performed 
using the following imaging conditions: Exposure time: 3.67 ms and Gain: 1.000. 
 
2.2.6.1 Single donor and multiple donors 
 The approximate amount of NBD to LP was determined as a ratio of moles of 
NBD to moles of LP. The moles of NBD were determined by comparison to an NBD 
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standard, and the moles of LP were determined by enzymatic assays as described in 
Section 2.2.5.  The ratios were found for NBD/TRL, NBD/LDL, and NBD/HDL. 
 
2.3 Clinical Studies 
2.3.1 Statistical methods for classifying CVD versus non-CVD samples 
2.3.1.1 Measurement of the lipoprotein subclasses by fluorescence  
 After obtaining an in situ density profile, the positions of the lipoprotein classes in 
the ultracentrifuge tube matched with the published values of the ranges of the 
lipoprotein subclasses, including new subclasses of the triglyceride-rich lipoproteins, 
which we have assigned the label buoyant (b-TRL) and dense triglyceride-rich (d-TRL) 
lipoprotein.29 The integrated intensity for the 12 subclasses in Table 2 were measured for 
each sample. 
 
2.3.1.2 Patient selection and defining groups  
 The two groups are defined as a control group and a CVD risk group. The criteria 
for selecting control group samples were donors with normal to elevated HDL 
cholesterol, normal LDL cholesterol, and clear angiogram. The CVD risk group samples 
were selected that exhibit elevated HDL cholesterol, normal LDL cholesterol, and 
documented atherosclerosis. 
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2.3.1.3 Application of LDA and SAVE 
Classification involves two groups using the 12 subclass parameters derived from 
the lipoprotein density profile. Data on the following variables bTRL, dTRL, LDL-1, 
LDL-2, LDL-3, LDL-4, LDL-5, HDL-2a, HDL-2b, HDL-3a, HDL-3b and HDL-3c were 
provided for 15 matched control subjects and 15 subjects with CVD. The data was 
analyzed using linear discriminant analysis (LDA) and sliced average variance 
estimation (SAVE). Statistical methods were applied using SPSS statistics software 
(Chicago, IL). 
 
2.3.2 Measuring the lipid content of lipoprotein subclasses 
 Samples were recovered from the centrifuge tube using the freeze slice method 
described in section 2.2.5.1. LDL subclass was assayed for cholesterol content, and TRL 
subclasses were assayed for triglyceride contents using commercial kits.  
 
2.3.2.1 Single donor 
The parameters described above were followed for the UC separation, and the 
serum volume was varied: 10, 20, 30, 40, and 50 µL. The integrated fluorescence 
intensities for dense TRL, buoyant TRL, and LDL were plotted as a function of serum 
content in samples. Additionally, integrated intensities of dense TRL, buoyant TRL, and 
LDL were plotted as a function of measured TG and Cholesterol concentrations. TG and 
Cholesterol concentration were measured by enzymatic assay as described above. 
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2.3.2.2 Randomly selected donors under saturation conditions 
Ten randomly selected patient samples were examined for TG and Cholesterol 
content similarly as the single donor with minor modification. The lipoprotein subclasses 
were isolated from UC separation under saturation conditions as described in section  
 
2.3.2.3 Utilizing 6µL of serum  
The measured integrated intensities for LDL were plotted versus the cholesterol 
content, and the measured integrated intensities for buoyant and dense TRL were plotted 
versus the TG content. 
 
2.3.3 Special study: Effects of statin therapy on lipoprotein profiles 
For this study donors were selected from our library of samples that exhibit high 
risk for heart disease and are receiving either statin or placebo medication. Serum draws 
were taken at 0, 24, 48, and 60 weeks to monitor long-range changes to the donors 
lipoprotein density profile. Ultracentrifuge separations were performed as described in 
Section 2.2.3. 
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CHAPTER III 
RESULTS AND DISCUSSION  
 
 The overall objective of this study was to develop a precise method for 
measuring the concentration of serum lipoproteins as a function of their density. To meet 
this objective, several developmental studies were conducted and combined to produce a 
clinically viable protocol. After the decision was made to incorporate a fluorescent tag 
into the lipoprotein for quantitation, the kinetics of uptake were studied to establish 
equilibrium conditions. The first study here summarizes these findings.  
 Following this study, the conditions for forming the density gradient in the 
ultracentrifuge tube and precise determination of the gradient profile was established.  
This was the objective of the second study. 
 Once the conditions for fluorescence tagging and ultracentrifugation were 
established, the problem of imaging the fluorescent profile was addressed. A phantom 
tube was constructed to simulate the density profile to establish imaging parameters.  
Then the dynamics of a lipoprotein particle under ultracentrifugation conditions was 
simulated using fluorescent nanospheres with the density of HDL, and these 
measurements determined the intrinsic resolution.  
 The studies using serum samples were initiated using samples from healthy 
volunteers, established the protocol for obtaining integrated fluorescence intensities of 
the lipoprotein classes, and correlated the fluorescence intensity with lipid composition. 
Finally, a pilot clinical study was carried out using this technology to study subjects who 
  40 
have atherogenic HDL. Novel  methods of statistical classification were employed using 
fluorescence intensity data from the lipoprotein density profiles to distinguish between 
subjects with cardiovascular disease from healthy controls. 
 
3.1 Analytical Methods 
3.1.1 Saturation/kinetics studies 
Serum lipoproteins have been fluorescently labeled for detection in capillary 
systems.9 NBD C6-ceramide is an ideal tag for labeling lipoproteins since it is only 
fluorescent when it is incorporated into a hydrophobic environment making NBD highly 
specific for lipoproteins. We have adopted a similar tag system for detection in the 
ultracentrifugation system.15 Due to the influence of biological differences from sample 
to sample, the amount of fluorophore incorporated into lipoproteins will vary; therefore 
it is critical to use sufficient fluorophore to ensure maximum incorporation is achieved 
regardless of sample. This will allow us to analyze differences in fluorescence intensity 
that are caused by differences of the lipoprotein characteristics, and not due to 
insufficient fluorophore incorporation. 
 
3.1.1.1 Determination of serum LP saturation point with NBD fluorescent tag 
The fluorescence response for major classes of lipoproteins (TRL, LDL, HDL 
and Serum Proteins) is measured from the density profiles. Figure 8 shows the plot of 
fluorescence intensity as a function of fluorophore content. It is found that a minimum of 
5 µL of 1 mg/mL NBD C6-ceramide is required to saturate all the subclasses in a 6 µL 
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sample for a donor with moderately elevated lipid levels. For all clinical studies this 
value is doubled to ensure that sufficient NBD C6-ceramide is present for staining all 
lipoproteins.  
 
 
Figure 8. Fluorescence response of major lipoprotein subclasses as a function of 
NBD C6-ceramide added shows that a minimum of 5µL of NBD C6-ceramide is 
required to saturate a 6µL sample of serum for a donor with moderately elevated 
lipid levels.  
 
3.1.1.2 Determination of serum LP uptake of fluorescent label NBD as a function of time 
Since the NBD has a relatively high density it is important to ascertain the 
required time for staining the lipoproteins prior to beginning the density separation, or it 
may separate from buoyant lipoproteins before proper staining. Figure 9 shows the time 
elapsed evolution of serum lipoproteins during incorporation of NBD C6-ceramide . This 
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was performed by monitoring the intensity at the emission maximum (520 nm) while 
exciting the serum matrix at the excitation maximum for NBD (450 nm).  From the time 
trace we find that it is necessary to incubate the lipoproteins with the NBD dye for a 
minimum of 35 minutes prior to beginning the separation. 
 
 
Figure 9. Fluorescence evolution due to incorporation of NBD fluorophore into 
serum lipoproteins as a function of time. 
 
 Additionally, figure 10 shows the emission scan for a lipoprotein sample before 
and after incubation with NBD C6-ceramide. Prior to the addition of NBD tag to the 
sample there is no appreciable fluorescence. After the incubation with NBD the 
fluorescence response curve observed is indicative of NBD fluorescence. This clearly 
illustrates the specificity and effectiveness of using NBD as a fluorescent tag for LP.  
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Figure 10. Fluorescence response of a lipoprotein sample before and after 
incubation with NBD C6-ceramide. 
 
 From this study, it is determined that the optimized conditions for analyzing 
serum lipoproteins with NBD C6-ceramide is to stain 6µL of serum with 10µL of 
1mg/mL NBD C6-ceramide. The mixture requires a minimum of 35 minutes of 
incubation to fully saturate the lipoproteins.  
 
3.1.2 Lipoprotein density profiling 
3.1.2.1 Hydrodynamic properties of NaBiEDTA solutions 
In order to determine the density of a gradient profile, a calibration curve was 
constructed that relates the refractive index of the solution to the density of the solution. 
A series of ten NaBiEDTA solutions were made for the construction of calibration 
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curve. Figure 11 shows the resulting calibration curve. 
 
 
Figure 11. Calibration curve relating refractive index of NaBiEDTA solution to 
density measured at 20°C.  
 
 
3.1.2.2 Gradient formation and measurement 
After centrifugation, the gradient shape was determined by removing aliquots 
from discrete positions within the gradient and measuring their refractive index. Each 
tube was sampled sequentially from the top so that the gradient below each aliquot was 
not disturbed. Tubes were imaged while the sample was being removed so the exact 
location of each aliquot could be determined by digital analysis. By use of the calibration 
curve and the images of the sequential draws, the density of the solution can then be 
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plotted as a function of tube coordinate. Figure 12 shows the resulting curve from the 
samples of the density gradient with respect to their tube position.  
 
 
Figure 12. Gradient curve is constructed by taking aliquots sequentially from UC 
tube and comparing the refractive index to the calibration curve.  
 
3.1.2.3 Phantom tube 
 A phantom tube was used to assess certain response features of the imaging 
system, primarily to address the concern of band broadening to the omni-directional 
emission of fluorescent light. The phantom tube is constructed to mimic a lipoprotein 
density separated tube with similar fluorescence features containing both fluorescent and 
non-fluorescent layers. By constructing a solid matrix, the layers can be physically 
measured and then compared to the size of bands that are produced in the image profile.  
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Figure 13. Image profile produced by the phantom tube.  
 
The physical measurements of the three fluorescent bands are as follows: Band 1 from 
6.75 to 8.75, Band 2 from 12.75 to 16.75, Band 3 from 22.5 to 27.75. Figure 13 shows 
the image profile produced by the phantom tube. From the image we find that the bands 
are as follows: Band 1 from 6.7 to 8.7, Band 2 from 12.7 to 16.7, Band 3 from 22.3 to 
27.7. From this data we find that the average percent error for these measurements is 
0.5%. Additionally since the gaps between bands drops to baseline there is very minimal 
band broadening visible due to the omni directional emission of fluorescent light. We 
can therefore conclude that in a serum profile any intensity above baseline is in fact 
indicative of the presence of lipoproteins in that space. 
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3.1.2.4 Replicate measurement of nanosphere standard 
In this study, polycarbonate fluorescent beads are used as a density marker. The 
advantage of using these particles as a density marker is that they have a highly mono-
disperse density. This allows us to assess the resolution of our gradient and the 
reproducibility of the peak position in the density profile. Replicate measurements of the 
gradient were performed to evaluate the reproducibility of the gradient formation.   
 Figure 14 shows the density profile for the fluorescent polycarbonate spheres. 
From 20 replicate measurements we find that the position of the peak on average is 
25.00 ± 0.06mm. The 95% confidence limit for our system is found to be ±0.0263 mm, 
and a coefficient of variance of 0.24%. From this data we find that the density gradient 
formation for our EDTA salts is highly reproducible. Additionally, when running serum 
samples a standard tube containing the polycarbonate sphere can be also run to monitor 
the integrity of the ultracentrifuge separation.  
 In addition to using the polycarbonate spheres as a monitor of the gradient 
formation, they can be used to monitor the light source intensity. The integrate 
fluorescence intensity of the 20 replicates is likewise analyzed. It is found that the 
average integrated intensity for the spheres is 1890 ± 130.18, with a 95% confidence 
limit of 57.05, and a coefficient of variance of 7%. Spinning a tube of polycarbonate 
fluorescent spheres in the rotor with the serum samples will allow us to monitor the 
integrity of the data that is collected for subsequent clinical studies and estimate the 
density resolution. 
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Figure 14. Density profile of 100 nm fluorescent polycarbonate spheres in 0.2M 
NaBiEDTA gradient.  
  
3.1.2.5 Ultracentrifugation of serum samples and image analysis 
Lipoprotein density profiling is a critical tool for risk assessment of CHD since 
the lipoproteins function and integrity is greatly related to its density and class. After 
ultracentrifugation is performed to separate the lipoprotein classes, the density profile is 
generated by analysis of light intensity of the central vertical axis of the image of the UC 
tube as shown in figure 15. 
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Figure 15. The density profile is generated by evaluating light intensity of the 
vertical central axis of the UC tube image.  The top of the tube is shown as the left 
position on the profile. 
 
 Figure 15 shows the major lipoprotein subclasses in the density profile. Panel a) 
shows the actual separation taken immediately following the UC separation. In this 
separation, the bTRL and dTRL are not resolved given that the density at the meniscus is 
slightly greater than 1g/ml. The sample is therefore layered with an aliquot of 200 µL of 
H2O to resolve the bTRL and dTRL by allowing the bTRL to float up with the meniscus. 
The resulting separation is shown in Figure 16 (b).  
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Figure 16. (a) Lipoprotein density profile (unlayered) in NaBiEDTA. (b) 
Lipoprotein density profile in NaBiEDTA following the layering of H2O. 
 
In this study, the method for determining the gradient curve was shown and its 
use for separating major lipoprotein subclasses was illustrated. Additionally, a method is 
established for the separation of  bTRL and dTRL.  
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3.1.3 Reproducibility of density profile measurement 
 Historically, ultracentrifugation has been primarily used as a qualitative and 
preparative tool. In this study we show the highly reproducible nature of our specific 
density gradient system. Additionally we show the reproducibility of our fluorescence 
detection for the purpose of using density profiling as a quantitative tool.  
 
3.1.3.1 Replicate measurements of a standard serum sample 
 Ten replicate measurements of a standard serum sample were performed to 
assess the reproducibility of the lipoprotein density profile. The integrated intensities 
were measured for the 12 lipoprotein subclasses as is shown in figure 17. Figure 17 
shows the replicate density profiles for the standard serum sample. From the profiles it is 
readily apparent that overall the density profiles are very reproducible. The primary 
deviation arises at the layering interface. This was expected do to the difficulty of 
reproducibly layering H2O on top of the gradient.  
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Figure 17. Shows the replicate profiles for a standard serum sample.  
 
Analysis of the integrated intensity for the subfractions shown in Table 3, as 
performed for the clinical studies, reveals that the coefficient of variance was relatively 
small between replicate measurements of about 7-8%. The largest variability was 
exhibited at the layering interface between dTRL and LDL-1 but even this is around 8% 
variance. Otherwise this method is very repeatable. For samples that do not require 
layering (i.e. HDL and LDL studies), a higher degree of repeatability is expected. 
Particularly for subclasses found near the center of the UC, the variance is as low as 3%. 
This can be taken advantage of by tailoring the EDTA gradient to separate desired 
subclasses in the center of the UC tube.  
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Table 3. Lists the integrated fluorescence intensity values for the replicate 
measurements of the standard serum sample. 
 
Sample bTRL dTRL 
LDL-
1 
LDL-
2 
LDL-
3 
LDL-
4 
LDL-
5 
HDL-
2b 
HDL-
2a 
HDL-
3a 
HDL-
3b 
HDL-
3c 
1 14386 15096 1241 5297 9115 9876 3198 4613 6957 14240 7635 3653 
2 13169 15670 1222 5465 8873 8666 2873 4321 6428 12412 7334 3719 
3 11107 15324 1000 5629 7861 7558 3100 4175 5464 11353 7012 3235 
4 14647 14141 1146 5797 8943 9263 2999 4416 6555 12799 7195 3754 
5 14558 15739 1210 5635 8937 9282 3205 4421 6368 13829 8504 4318 
6 14247 15620 1266 5700 9223 9641 3129 4528 6465 13494 8358 3871 
7 14611 15662 1033 5478 8722 9327 3225 4343 6660 12694 6881 3553 
8 14695 16020 1044 5626 8740 9297 3214 4361 6720 12658 6821 3623 
9 14717 15275 1147 5166 8551 9386 3240 4353 6630 12812 6905 3538 
10 14857 18397 1211 5579 9254 9878 3241 4621 6993 14455 7734 4075 
Avg 14100 15694 1152 5537 8822 9217 3142 4415 6524 13075 7438 3734 
Std Dev. 1155 1080 95 190 405 680 122 139 427 935 609 301 
Coefficient 
of Variance 8 7 8 3 5 7 4 3 7 7 8 8 
 
 
3.1.3.2 Biological variability 
 When profiling serum of a single donor drawn at different times, variations in the 
profile can arise that are not due to the experimental process. Changes due to the donor’s 
body chemistry constantly affect the density profile that can be obtained and, likewise, 
their level of risk. Biological effects that may change the serum profile are observed by 
profiling the serum of a donor as described above at the following interval: one day, one 
month, one year. It is important to assess changes in a person’s life, particularly when 
applying this technique to time elapsed studies where the effects of lifestyle, age, and or 
medications all influence the person’s risk level and, likewise, their density profile.   
Figure 18 show the density profiles for a donor at various intervals. It is readily 
apparent that on a short term basis there is very minimal change to the profile shape, 
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which means that the predominant lipoprotein species are relatively consistent. 
However, on longer time scales changes in lifestyle/activity can greatly influence the 
predominant lipoprotein profile, which is evidenced by the 1-year trace. For this 
volunteer, it is known that there was a dramatic change in diet and exercise level in this 
time frame, and the increased levels of dense LDL subclasses in the 1-year trace are 
indicative of higher risk. This correlates with the donor’s lower activity and poorer diet 
at the time of the serum draw. 
 
 
Figure 18. Density profiles for a single donor at various intervals.  
 
 In this study we show the precision of using complexes of EDTA as a gradient 
solution and the precision of the imaging system employed to generate the density 
profiles. From this analysis we conclude that we can very accurately determine the 
density of lipoproteins and additionally apply this method to ascertain changes that a 
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person may experience to their risk levels over time.  
 
3.1.4 Analysis of serum lipoprotein fractions 
 The purpose of this study is to ascertain the precision of our method utilized for 
excising serum fractions from the UC separation. This is a critical step in combining the 
UC method with MALDI, CE, and enzymatic assays. 
 
3.1.4.1 Lipoprotein fraction collections 
Lipoprotein fractions were collected from the polycarbonate tube by a 
freeze/slice method where the tube was first frozen in liquid nitrogen and then cut for 
collection. After determining the tube coordinates of the frozen tube we then ascertain 
the precision of the slicing method by scoring UC tubes and imaging the position of the 
cut. Figure 19 shows the profile of the scores on the UC tube and the calculated ideal 
positions. The peak center varied by ± 0.5mm when using a blade width is 0.25mm.  
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Figure 19. Profile of a UC tube that has been scored to determine the precision of 
freeze/slice method. 
 
 From the scoring, we determine that we can precisely excise fractions at least 
2mm in size. When we combine this with tailored density gradients, we can more 
effectively characterize various lipoprotein subclasses by changing the resulting density 
profile.  
 
3.1.5 Approximation of LP/NBD stoichiometry  
This study aims to determine an approximate ratio of NBD C6-ceramide to 
lipoproteins to determine and approximate stoichiometry. This is measured by 
determining the fluorescence intensity of different lipoprotein fractions separated by 
density gradient ultracentrifugation and comparison to a standard sample of NBD. These 
values were used to determine percent distribution throughout the lipoprotein classes as 
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a function of density. We quantify the number of fluorophores that are incorporated into 
a favorable dielectric environment in a serum sample by comparison with an NBD 
sample in Chloroform from the integrated fluorescence intensity. Additionally we 
measure the effect of ultracentrifugation on the fluorescence intensity of a serum sample.  
 
3.1.5.1 Stoichiometry of NBD to serum Lipoproteins for single donor and multiple 
donors 
NBD C6-ceramide is an amphiphilic molecule that is fluorescent when it is in a 
hydrophobic environment due to favorable dielectric and is not fluorescent in an aqueous 
environment. As a result of the molecule’s structure, NBD C6-ceramide is incorporated 
into micelles when placed in an aqueous environment, and can be used as a fluorescent 
tag for lipoprotein. Its fluorescence can be excited by use of wavelengths from 440-
490nm and results in a maximal emission around 520-540nm. Due to NBD’s unique 
characteristics, we quantify the number of fluorophores that are incorporated into a 
favorable dielectric environment in a single donor sample by comparison with an NBD 
sample in Chloroform (100% incorporation to favorable dielectric). From the integrated 
fluorescence intensity, we conclude that 16% of the available NBD have been 
incorporated into a fluorescently favorable environment in the serum sample. 
Additionally we measure the effect of ultracentrifugation on the fluorescence intensity of 
a serum sample.  
Table 4 lists the values determined for a single donor. The integrated intensity 
values were determined from the density profiles. The moles of TRL and LDL were 
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determined by commercial assay for apo B, and the moles of HDL were determined by 
commercial assay for apo A1. 
 
Table 4. Competitive interactions of NBD C6-ceramide and lipoproteins. 
 
 
 
The ultracentrifugation has a small effect of “stripping” NBD from the 
lipoproteins by reducing fluorescence intensity by about 10%. Based on the change of 
integrated intensity change it is concluded that there is a small number of NBD particles 
that are being stripped off the lipoproteins during the ultracentrifugation.  However, this 
change is small and means that the NBD/LP complex is rather robust. 
A comparison is made between the serum sample and a standard sample and it is 
determined, using Equation 4, that approximately 15-16% of available NBD 
fluorophores are incorporated into a favorable environment for fluorescence to occur in 
the serum sample.  
 
Percentage = Integrated Intensity of serum sample
Integrated Intensity of chloroform sample
×100   (Equation 4) 
 
  
Integrated 
Area 
Percentage of 
total population 
in a fluorescent 
state 
Moles NBD in 
fluorescent 
state 
Conc. Protein 
(moles/µL) 
determined by 
Immunoassay 
Moles 
Protein 
Moles 
NBD/Protein 
NBD in 
Chloroform 24274.93   1.36E-08       
Before Spin 4045.24 16.66 2.27E-09       
After Spin 3664.44 15.10 2.05E-09       
TRL 607.68 2.50 3.40E-10 1.63E-13 8.82E-13 385.998 
LDL 1262.39 5.20 7.07E-10 5.80E-11 3.13E-10 2.258 
HDL 875.44 3.61 4.90E-10 1.10E-09 5.94E-09 0.083 
Serum Proteins 956.48 3.94 5.36E-10       
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The percentages of NBD in a fluorescent state are determined by comparison of 
the integrated intensities of the fractions and the chloroform standard, then the number 
of moles of NBD in a fluorescent state in each fraction are determined by Equation 5. 
 
# Moles fluorescent =% of NBD in the fraction ×Total Moles of NBD  (Equation 5) 
 
The stoichiometry of NBD to lipoproteins was then determined by a ratio of 
moles NBD fluorescing to moles of lipoprotein. For this donor it is determined that the 
ratio of NBD/TRL is approximately 390, ratio of NBD/LDL is 2, and the ratio of 
NBD/HDL is 0.1. 
 In addition to determining the ratio for a single donor, nine randomly selected 
donors were treated similarly to determine the ratios of NBD/LDL and NBD/HDL. TRL 
subclasses have a high amount of heterogeneity arising from the layering process and 
because of larger variability from patient to patient. Due to the heterogeneity of TRL it 
was disregarded in this study. Table 5 lists the values determined for these samples. 
The average ratio of NBD/LDL was determined to be approximately 2 
fluorophore molecules per LDL, and the average ratio of NBD/HDL was determined to 
be approximately 1 fluorophore molecules per HDL. However there is a considerable 
amount disparity between samples that arises due to patient variability.  
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Table 5. Lists values for determining the stoichiometry of 9 randomly selected 
subjects. 
 
  
Integrated 
Intensity 
moles of fluorescent 
NBD Moles of LP Stoichiometry 
HDL 
Subject LDL HDL LDL HDL 
LDL 
(pmol) (pmol) 
moles 
NBD/moles 
LDL 
moles 
NBD/moles 
HDL 
1 1857 2360 5.50E-10 7.00E-10 311 1557 1.77 0.45 
2 1696 2009 5.10E-10 6.00E-10 316 1072 1.61 0.56 
3 1981 1881 5.90E-10 5.60E-10 325 772 1.82 0.73 
4 2298 1483 6.80E-10 4.40E-10 320 452 2.13 0.97 
5 1910 1844 5.70E-10 5.50E-10 419 652 1.36 0.84 
6 2214 1943 6.60E-10 5.80E-10 343 602 1.93 0.96 
7 1387 1420 4.10E-10 4.20E-10 217 437 1.89 0.96 
8 1739 1824 5.20E-10 5.40E-10 455 776 1.14 0.70 
9 1584 1938 4.70E-10 5.70E-10 300 803 1.57 0.71 
      Average 1.69 0.76 
      St. Dev 0.30 0.19 
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3.2 Clinical Studies 
3.2.1 Measuring the lipid content of lipoprotein subclasses 
 The objective of this study was to establish a correlation of the lipid composition 
of a lipoprotein subclass with its fluorescence intensity. Samples were recovered from 
the centrifuge tube and analyzed for total cholesterol and triglycerides using commercial 
assays.  
 
3.2.1.1 Determination of relationship of lipid content to NBD fluorescence  
Due to NBD C6-ceramides unique attributes, its fluorescence appears to be 
related to the major lipid component concentration of a lipoprotein.  This means that for 
LDL the fluorescence is associated with LDL cholesterol, LDL’s major lipid component. 
A standard serum sample was used to determine if increasing cholesterol concentration 
was related to the density profiles by varying the serum volume used in the UC 
separation. 
 LDL cholesterol concentration was determined by enzymatic assay applied to 
the LDL fraction. The integrated fluorescence intensities for LDL was plotted as a 
function of cholesterol concentration in samples to determine if a linear relationship 
exists between fluorescence intensity and increasing lipid content. Figure 20 shows the 
plot of fluorescence intensity as a function of cholesterol concentration.  
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Figure 20. Shows the relationship between LDL integrated intensity versus 
cholesterol concentration for a single donor. 
 
 For a single donor, there is a strong relationship between the fluorescence 
intensity and the LDL cholesterol concentration with an R2 value of 0.96. This suggests 
that NBD C6-cermaide incorporation to favorable fluorescent domains is associated with 
the cholesterol content of a lipoprotein  
Similar to LDL, the TRLs were analyzed for their primary lipid component, 
triglycerides. For these fractions, integrated intensities of dTRL and bTRL were plotted 
as a function of measured TG concentrations. Triglyceride concentrations were 
determined by enzymatic assay applied to the TRL fractions. The integrated 
fluorescence intensities for TRL were plotted as a function of TG concentration in 
samples to determine if a linear relationship exists between fluorescence intensity and 
increasing lipid content. Figure 21a shows the plot of fluorescence intensity as a function 
of TG concentration for dTRL, and figure 21b shows the fluorescence intensity as a 
function of TG concentration for bTRL.  
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Figure 21. a) Plot of bTRL fluorescence intensity versus TG concentration for a 
single donor b) Plot of dTRL fluorescence intensity versus TG concentration for a 
single donor. 
 
 For a single donor, there is a strong relationship between the fluorescence intensity 
and the bTRL TG concentration with an R2 value of 0.93. This suggests that NBD C6-
cermaide incorporation to favorable fluorescent domains is associated with the TG 
  64 
content of a lipoprotein. For dTRL, the relationship is a little lower with an R2 value of 
0.81, and is likely a result of the layering process. As was seen in an earlier study, the 
variance at the layering interface between the dTRL and LDL-1 fractions is higher due 
to turbulence caused during layering of H2O onto the density gradient. 
To expand on this study ,10 randomly selected normolipidemic samples were 
examined similarly with minor modification. The 10 samples were examined using the 
saturation conditions established in section 2.2.3.3. The integrated intensities for LDL 
fractions were plotted versus the cholesterol concentration.  
 
Figure 22. Plot of LDL integrated intensity versus concentration of cholesterol for 
10 donors.  
 
Figure 22 shows the LDL integrated intensity as a function of cholesterol 
concentration. For normolipidemic samples there is a very strong relationship between 
LDL fluorescence and the cholesterol concentration with an R2 value of 0.91.  
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 Similar to LDL, the TRLs were analyzed for their primary lipid component, 
triglycerides.. Figure 23 shows the plot of fluorescence intensity as a function of TG 
concentration for dTRL.  
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Figure 23. Show the relationship of integrated fluorescence intensity for dTRL with 
respect to the TG concentration in the bTRL subclass. 
 
 The relationship for the dTRL subclass is moderate with an R2 value of 0.72. The 
relationship was weaker than that of a single donor. This is likely due to factors such as 
contributions from the layering process and also the larger heterogeneity that exists in 
the TRL subclass since it contains both VLDL and chylomicrons.  
 Similar to dTRL, the bTRL was analyzed for its primary lipid component, 
triglycerides. Figure 24 shows the plot of fluorescence intensity as a function of TG 
concentration for bTRL. 
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Figure 24. Show the relationship of integrated fluorescence intensity for bTRL with 
respect to the TG concentration in the bTRL subclass. 
 
The relationship for the bTRL subclass is moderate with an R2 value of 0.80. The 
relationship was weaker than that of a single donor. This is likely due to large 
heterogeneity that exists in the TRL subclass since it contains both VLDL and 
chylomicrons.  
 
3.2.2 Statistical methods for classifying CVD versus non-CVD samples 
 The classification of patients that are at risk for cardiovascular heart disease is of 
paramount importance and critical to the discovery phase of diagnosis in medicine. 
Currently, the risk factors used clinically can effectively predict about 80 percent of 
heart disease victims. However, there is a segment of heart disease patients that do not 
exhibit the traditional risk factors of high LDL-c and low HDL-c. The aim of this study 
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was to determine the feasibility of classifying between a control group and a CVD group 
without the traditional risk factors. 
 
3.2.2.1 Classification analysis for distinguishing subject groups in a clinical study  
Once the method for analyzing the lipoprotein profile was established, the 
subclass analysis was expanded by incorporating the use of statistical methods for group 
classification. The groups were classified by using the integrated fluorescence intensities 
of the 12 subclasses defined in table 2. Two groups of samples are used where one group 
has exhibited no atherosclerosis (control group), which is determined by angiogram, and 
a group that has documented atherosclerosis (CVD group).  All subjects in this pilot 
study exhibit normal LDL levels and normal to high HDL levels. This means that under 
the traditional risk factors they should not be at risk for heart disease. The objective of 
this study was to determine whether the two groups could be classified based on their 
lipoprotein density profile.  
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Table 6: Integrated fluorescence intensity values of 12 lipoprotein subclasses for 30 
donors. 
 
Patient 
ID bTRL dTRL LDL-1 LDL-2 LDL-3 LDL-4 LDL-5 
HDL-
2b 
HDL-
2a 
HDL-
3a 
HDL-
3b 
HDL-
3c CVD 
Pt 0165 41171 12918 2903 13230 15352 12961 12621 28882 30668 40040 33762 16315 2 
Pt 0168 37387 11534 3651 18142 29607 24647 19421 47162 44564 53129 42427 19675 2 
Pt 0170 34574 25055 4452 17765 26308 19900 14370 29212 30703 38939 32941 16662 2 
Pt 0006 37771 11050 3360 15746 23877 17458 17077 41813 32371 43164 35464 16278 2 
Pt 0010 74226 22760 5396 22660 31615 28585 21208 46289 42474 74672 66995 28449 2 
Pt 0041 65853 31990 5355 25190 48004 41416 26438 34597 26146 41468 46996 23315 2 
Pt 0066 72515 32665 5257 24892 29538 32842 19672 15058 10904 19024 21256 11931 2 
Pt 0088 26361 11309 2450 10039 9968 8052 7241 19196 19690 23298 21284 11694 2 
Pt 0126 86670 46984 4201 20481 38370 54065 27341 30765 22255 28212 26900 13892 2 
Pt 0142 57788 75607 8966 31792 34036 33952 21701 20379 14778 16877 19634 14589 2 
Pt 0143 35643 14589 3188 13750 21132 21213 13170 22553 14350 17735 24012 16380 2 
Pt 0144 42734 32027 6531 21877 33789 23206 14943 27813 20216 30534 28664 14455 2 
Pt 0146 62079 53090 9730 40596 56775 34070 30542 62930 45036 69878 51442 21958 2 
Pt 0175 40185 13162 2838 25076 66189 27747 21790 53118 42384 40084 29707 15035 2 
Pt 0176 20263 8767 2172 11229 17233 15468 17442 45240 36191 35264 26018 13202 2 
Pt 0047 55183 28625 6042 32049 51848 40749 20456 30244 29206 54744 55145 24300 c 
Pt 0079 57171 33035 5837 35134 57143 56920 29218 23509 19802 36678 41724 24459 c 
Pt 0095 160604 64800 5535 26698 34046 34366 20756 23397 10792 13448 18485 15358 c 
Pt 0129 62568 37079 6486 34556 74261 75805 22705 21938 21191 29940 30240 16805 c 
Pt 0135 27047 18605 4044 19424 37430 24260 14091 34227 33604 53491 47000 17922 c 
Pt 0049 47239 46500 7929 39842 65095 38752 13238 18023 18746 26909 28057 16010 c 
Pt 0055 48786 21648 3611 15199 27358 31160 14033 13613 11525 25830 35019 19745 c 
Pt 0072 28496 10161 3174 20416 43378 21376 9923 13854 12305 25322 28312 16052 c 
Pt 0076 37170 24965 3719 19752 72485 35317 14060 14982 12631 21000 25101 15899 c 
Pt 0081 71473 35626 6229 35206 44706 52300 35359 18059 10950 21715 30327 19752 c 
Pt 0082 59878 58214 12584 54136 62782 46292 22284 18388 16592 33420 42050 24108 c 
Pt 0087 65394 29399 5445 28601 62123 35841 16085 16625 12238 27946 42107 31291 c 
Pt 0121 50669 21413 3880 17775 23007 29307 27955 13716 6606 13472 21193 17974 c 
Pt 0123 42034 14153 6271 18033 40404 30224 13800 20057 20466 29338 27877 15307 c 
Pt 0154 43990 16701 4975 39548 90328 31299 11744 16446 16258 34028 34470 18790 c 
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3.2.2.2 Application of LDA and SAVE 
For classification we use two techniques linear discriminant analysis (LDA) and 
sliced average variance estimation (SAVE). These two techniques are somewhat similar 
in that they both seek to find a linear combination of variables for classification. The 
primary difference between the techniques is that LDA finds linear combination in terms 
of the variables, while SAVE finds linear combinations in terms of the mean variance 
and covariance. The preliminary results obtained from LDA and SAVE are reported. All 
the predictor variables were log-transformed versions of the variables listed in Table 6.  
Working with ratios of variables has the advantage that sources of systematic error such 
as variability in light intensity are cancelled out. For this data set, the equation for LDA 
is given as follows: 
 
( )
1.702
1.196
1.42
1.196log(LDL 3) 1.702log(HDL 2b)
LDL 31.196log
HDL 2b
LDL 31.196log HDL 2b
− − + −
⎛ ⎞−= − ⎜ ⎟−⎝ ⎠
−= − −
 
 
The two most important variables in the LDA linear combination were found to 
be log [LDL-3] intensity and log [HDL-2b] intensity. Back transforming the logs, we 
find that the relevant ratio of these two predictors is LDL-3/HDL-2b1.42. By using just 
this relationship LDA separates 83.3% of the 30 cases correctly as either CVD or 
control. This is graphically depicted by the dot figure in figure 25.  
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Figure 25. Dot plot of LDL-3/HDL2b1.42 shows that use of this ratio correctly 
separates 25 (83%) of the samples and only 5 samples (17%) are overlapping with 
the opposite class.  
 
 Similarly, SAVE seeks to find linear combinations of the predictor variables 
which best separates the two groups in terms of the mean, variance and covariance of 
these linear combinations. This makes SAVE a multidimensional separation. The 
equation for the first SAVE dimension is given as follows. 
 
0.20 0.18
-15.206log(HDL-3a) + 13.022log(HDL-3b)+8.634log(HDL-2a) -3.084log(HDL-3c) 
+ 3.020log(LDL-2)-2.664log(HDL-2b) -1.458 log(LDL-1)-1.364log(dTRL)-0.906log(LDL-3)
HDL-3a HDL-3c HDL-2b LDL15.206log × × ×= −
0.10 0.09 0.06
0.86 0.57 0.20
-1 dTRL LDL-3
HDL-3b  HDL-2a  LDL-2
⎛ ⎞× ×⎜ ⎟× ×⎝ ⎠
 
 
Therefore it is concluded that the relevant term for the first SAVE dimension is given 
by: 
 
0.20 0.18 0.10 0.09 0.06
0.86 0.57 0.20
HDL-3a HDL-3c HDL-2b LDL-1 dTRL LDL-3
HDL-3b  HDL-2a  LDL-2
× × × × ×
× ×  
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The equation for the second SAVE dimension is given as follows. 
 
0.59 0.32 0.15
7.435log(HDL-3b) - 5.817log(HDL-3c)+ 4.412log(LDL-2)-2.933log(HDL-3a) -2.463log(LDL-3)
+2.371log(LDL-4)-2.305log(LDL-5) -1.599log(bTRL)+1.106log(HDL-2b)
HDL-3b LDL-2 LDL-4 HDL-2b7.435log
HDL
× × ×= 0.78 0.39 0.33 0.31 0.22-3c  HDL-3a  LDL-3  LDL-5  bTRL
⎛ ⎞⎜ ⎟× × × ×⎝ ⎠
 
 
Therefore it is concluded that the relevant term for the second SAVE dimension is given 
by: 
0.59 0.32 0.15
0.78 0.39 0.33 0.31 0.22
HDL-3b LDL-2 LDL-4 HDL-2b
HDL-3c  HDL-3a  LDL-3  LDL-5  bTRL
× × ×
× × × ×  
 
Figure 26 shows a graphical representation of the two dimensions produced by 
SAVE for the data set in log transform. It is readily apparent that the slopes of the two 
lines in Figure 26 are very different. Therefore, the covariance or relationship differs 
across the control and CVD group. Thus, SAVE has found two linear combinations 
capable of classifying these two groups. Interestingly, the values of SAVE1 for the 
control group are relatively constant while they change dramatically for the CVD group. 
A natural next step is to ascertain which of the predictor variables is most important in 
the first dimension of SAVE. The most significant variables were found to be associated 
with HDL-3a and HDL-3b comparison of exponential power. Then by back 
transforming the logs, the relevant ratio of these variables is HDL-3a/HDL-3b0.86. 
Similarly we can analyze the second dimension of the SAVE analysis. In the second 
SAVE dimension the SAVE 2 values for the CVD subjects is relatively constant and 
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varies dramatically for the control subjects.  From this linear combination we find that 
the relevant ratio of these variables is HDL-3b/HDL-3c0.78.  
 
210-1-2-3
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Figure 26. A plot of the 2 dimensions of SAVE analysis reveals that there are two 
linear combinations that can distinguish between control and CVD subjects. 
 
The classification power can be improved by combining SAVE and LDA to 
produce a three-dimensional plot of the classification. Figure 27 shows a three-
dimensional plot of LDA, save1 and save2. It is clear from this plot that the two groups 
of points are very close to being disjoint (i.e., have very little overlap). The fact that the 
groups are so well separated is evidence that this analysis has successfully classified the 
cohorts almost perfectly. Interestingly, each significant ratio is a ratio of a subclass that 
is hypothesized to be cardio-protective and atherogenic. 
 
  73 
2
0
-2
-
-1
0
2
1
-2
0 -4
2
LDA
save1
save2
Control
CVD
Group
 
Figure 27. A 3-d plot of LDA and SAVE.  
 
 The immediate application of this technique would involve the determination of 
an individual’s classification by calculating their statistical values by using the equations 
for LDA and SAVE. An example of these calculations is given using the fluorescence 
values for Pt 0006. The LDA value for Pt 0006 is given as follows. 
 
LDA=−1.196log(LDL − 3) +1.702log(HDL − 2b) =−1.196log(23877) +1.702log(41813) =2.62
 
The SAVE 1 value for Pt 0006 is given as follows. 
 
SAVE 1= −15.206log(HDL − 3a) +13.022log(HDL − 3b) + 8.634 log(HDL − 2a)
−3.084 log(HDL − 3c) + 3.020log(LDL − 2) − 2.664 log(HDL − 2b) −1.458log(LDL −1)
−1.364 log(dTRL) − 0.906log(LDL − 3) =
−15.206log(43164) +13.022log(35464) + 8.634 log(32371) − 3.084 log(16278)
+3.020log(15746) − 2.664 log(41813) −1.458log(3360) −1.364 log(11050) − 0.906log(23877)
= 0.4590
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The SAVE 2 value for Pt 0006 is given as follows. 
 
SAVE 2 = 7.435log(HDL − 3b) − 5.817log(HDL − 3c) + 4.412log(LDL − 2)
−2.933log(HDL − 3a) − 2.463log(LDL − 3) + 2.371log(LDL − 4) − 2.305log(LDL − 5)
−1.599log(bTRL) +1.106log(HDL − 2b) =
7.435log(35464) − 5.817log(16278) + 4.412log(15746) − 2.933log(43164) − 2.463log(23877)
+2.371log(17458) − 2.305log(17077) −1.599log(37771) +1.106log(41813)
=1.563
 
 
This study not only demonstrates the efficacy of these classification methods, but 
also proves that there is sufficient statistical power (even with a limited subject base) to 
classify the two groups. This finding is all the more remarkable when we consider that 
the CVD group had normal LDL and HDL levels. Yet, both methods identified features 
in the density profile that were different for the two groups. Additionally, the statistical 
values for an individual can be determined by using the equations determined by LDA 
and SAVE. 
 
3.2.3 Special study: Effects of statin therapy on lipoprotein profiles 
Application of the UC density profiling for monitoring long-range changes is 
now possible. The objective of this study was to assess the effects of statin therapy on 
the lipoprotein profile. We accomplish this by measuring changes in the density profile 
over the period of a year. For this study donors were selected from our library of samples 
that exhibit high risk for heart disease and are receiving either statin or placebo 
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medication. Serum draws were taken at 0, 24, 48, and 60 weeks. Ultracentrifuge 
separations were performed as described in section 2.2.3.3.  
Reported here are two example subjects one is likely a placebo recipient and the 
other is likely receiving statin therapy. These two subjects are part of a larger clinical 
study involving Scott & White hospital. In an effort to maintain the studies integrity the 
identity of subjects receiving statin or placebo is not known in our laboratory. However 
visible changes to the profiles suggest to which group the subjects belong.  
Figure 28 shows the density profiles for the subject that is likely taking the 
placebo. It is evident from the profiles that there is a likely decline in health and 
therefore increased risk for heart disease. This is immediately evident due to the 
dominant LDL species. By week 48, the predominant LDL species is LDL-5. LDL-5 
corresponds to the small dense LDL subclass that has received much attention due to its 
role in atherogenesis.  
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Figure 28. a)Density profiles for placebo recipient b)Density profiles for statin 
recipient. 
 
Figure 28b shows the density profiles for the subject that is likely receiving statin 
therapy. It is evident from the profiles that there is a likely improvement in health and 
therefore decreased risk for heart disease. This is evident due to the dominant LDL 
species. By week 60 the predominant LDL species is LDL-2 and LDL-3. This more 
buoyant class of LDL is generally regarded as normal or healthy LDL.  
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There are many factors that can affect the lipoprotein distribution ranging from 
diet, exercise, and medication. The UC method described here can now be used as one of 
the tools that is applied to clinical studies aiming to better understand the role 
lipoproteins play in determining a person’s risk for heart disease.  
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CHAPTER IV 
CONCLUSIONS 
 
 The overall objective of this research was to develop an array of methods for the 
analysis and classification of lipoproteins in human serum, and to apply these methods to 
clinical samples. This objective was achieved by combining novel density gradient 
separations, fluorescent imaging, and enzymatic assays. Additionally, this objective was 
also achieved by examination of the experimental data with modern statistical methods 
for classifying groups. Furthermore, the density profiling technique and statistics was 
applied to a pilot group study involving a series of patients from Scott & White Hospital, 
Temple, Texas who exhibited normal LDL-c and normal to high HDL-c. This study 
yielded information that reveals a key feature of a lipoprotein profile that will indicate a 
patient’s level of risk, and more importantly reveals the feasibility for accurately 
classifying cohorts based on their fluorescent lipoprotein profile.  
 During the course of this research it was found NBD C6-ceramide quantitatively 
stains lipoproteins. NBD C6-ceramide is highly specific for lipoproteins in aqueous 
solution since no fluorescence is observed until it is incorporated into the lipoprotein 
structure. Also, NBD C6-ceramide is shown to have a strong relationship with the 
primary lipid components in the lipoproteins. Specifically, it is observed that NBD C6-
ceramide fluorescence correlates to the triglyceride content in TRLs and the cholesterol 
content in LDL. In addition, the sensitivity of the fluorescence technique allows for the 
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use of very minimal sample volume. This is a critical feature when dealing with clinical 
studies, as the patient’s blood will typically be screened for multiple different tests.  
 It was demonstrated that the metal EDTA complex as a gradient for separating 
lipoproteins is highly reproducible and showed a small variance for the subclass 
analysis. This allowed the measurement of subclasses of lipoproteins to be carried out 
with out the need of tedious and time consuming sequential centrifugation steps.  
A phantom tube was developed for the purpose of insuring the integrity of the 
measured position in the UC imaging system and establishing imaging parameters. It 
was found that the imaging accurately measures the position of the fluorescent bands 
with an error less the 0.5%. Additionally, the accuracy of the freeze/slice method was 
verified to have a small error. These two techniques can be used periodically to validate 
the imaging system and operator’s technique. By combining DGU imaging method with 
the freeze/slice method, subclasses can be excised from the gradient, and further analysis 
can be conducted on lipoproteins by subclass. DGU has been combined with MALDI-
MS, enzymatic assays, fluorescence, UV/VIS spectroscopy, gel electrophoresis, and 
capillary electrophoresis; however, many other techniques can also be explored due to 
the flexibility that DGU offers as a preparative/quantitative tool. 
 The dynamics of a lipoprotein separation were simulated by use of fluorescent 
polycarbonate spheres. The nano-spheres have a highly reproducible fluorescence and 
peak in the UC density profile, and by monitoring the position of a gradient containing 
these nano-sphere it is possible to ensure the integrity of the gradient and experimental 
procedure. It is shown that the inherent resolution of the density gradient is very high. 
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This method will play a critical role in quality assurance for the large-scale clinical 
studies.  
 DGU has also been shown to be a powerful tool for assessing long-range changes 
to an individual’s lipoprotein density profile. A person’s health can change dramatically 
depending on the time frame that is being considered. Changes in lifestyle, activity, diet, 
and medication all have an effect on the density profile. This means that the density 
profile can be used as a fingerprinting technique to assess the changes in risk that an 
individual may exhibit. This is clearly evidenced with the clinical study in distinguishing 
the difference between participants on statin therapy versus one on the placebo. It is 
readily apparent that there is a different trend occurring for the two groups.  
 Though the majority of research in the past has focused on the analysis of intact 
lipoproteins, more and more attention is turning to study the compositional changes of 
lipoproteins. Apo-protein assays were used to determine the concentration of apo-
proteins in a fraction, and therefore the concentration of a given lipoprotein. This was 
used to determine an approximate stoichiometry of NBD C6-ceramide to a lipoprotein. 
As expected, this result yielded a high amount of donor variability, and is likely due to 
the fact that NBD C6-ceramide seems to relate to the concentration of the major lipid 
component of a lipoprotein, and this can vary dramatically from person to person. 
Likewise, cholesterol and triglycerides of given subclasses have been directly 
measured by use of enzymatic assays combined with DGU. This combination yielded 
the ability to relate NBD C6-ceramide fluorescence to the concentration of the major 
lipid. The apparent relationship of NBD fluorescence to the lipid content of TRL and 
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LDL could potentially be exploited as a direct measure of the major lipid content. This 
would be an improvement over the existing method as it will be a more direct 
measurement rather than an indirect estimation.  
 Finally, classification power of combining our experimental methods with 
modern statistical techniques is a major outcome. There is a segment of the population 
that developed atherosclerosis despite not having the traditional risk factors. When DGU 
analysis is combined with modern statistical methods an effective and near perfect 
classification of a control group and a diseased group was achieved. By combining the 
subclass fluorescence measurements with use of LDA and SAVE method, two major 
predictors for these groups was determined to the ratio of HDL3a/HDL3b0.86.  
 The primary strength of these methods lay in the ability to analyze many aspects 
of an individual’s lipoprotein profile to attain an overview of a patients risk and probe 
lipoprotein activity. The work reported here establishes a method to distinguish between 
CVD and non-CVD donors that do not have the traditional risk factors. These findings 
will potentially lead to earlier diagnosis and treatment for patients, and will lead to 
improved understanding of the processes the lipoproteins. Future application of this 
work will explore the use of this technique on a more global population, as well as 
explore the significance of the relationships found with the statistical methods.  
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